Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - GAMG [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - hTERT-RPE1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - JURKAT [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - OE19 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - SuSa [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"	"Single Cell Type RNA - Alveolar cells type 1 [NX]"	"Single Cell Type RNA - Alveolar cells type 2 [NX]"	"Single Cell Type RNA - B-cells [NX]"	"Single Cell Type RNA - Basal glandular cells [NX]"	"Single Cell Type RNA - Basal keratinocytes [NX]"	"Single Cell Type RNA - Bipolar cells [NX]"	"Single Cell Type RNA - Cardiomyocytes [NX]"	"Single Cell Type RNA - Cholangiocytes [NX]"	"Single Cell Type RNA - Ciliated cells [NX]"	"Single Cell Type RNA - Club cells [NX]"	"Single Cell Type RNA - Collecting duct cells [NX]"	"Single Cell Type RNA - Cone photoreceptor cells [NX]"	"Single Cell Type RNA - Cytotrophoblasts [NX]"	"Single Cell Type RNA - Distal tubular cells [NX]"	"Single Cell Type RNA - Ductal cells [NX]"	"Single Cell Type RNA - Early spermatids [NX]"	"Single Cell Type RNA - Endothelial cells [NX]"	"Single Cell Type RNA - Enterocytes [NX]"	"Single Cell Type RNA - Erythroid cells [NX]"	"Single Cell Type RNA - Exocrine glandular cells [NX]"	"Single Cell Type RNA - Extravillous trophoblasts [NX]"	"Single Cell Type RNA - Fibroblasts [NX]"	"Single Cell Type RNA - Glandular cells [NX]"	"Single Cell Type RNA - granulocytes [NX]"	"Single Cell Type RNA - Hepatocytes [NX]"	"Single Cell Type RNA - Hofbauer cells [NX]"	"Single Cell Type RNA - Horizontal cells [NX]"	"Single Cell Type RNA - Intestinal endocrine cells [NX]"	"Single Cell Type RNA - Ito cells [NX]"	"Single Cell Type RNA - Kupffer cells [NX]"	"Single Cell Type RNA - Late spermatids [NX]"	"Single Cell Type RNA - Leydig cells [NX]"	"Single Cell Type RNA - Macrophages [NX]"	"Single Cell Type RNA - Melanocytes [NX]"	"Single Cell Type RNA - monocytes [NX]"	"Single Cell Type RNA - Mucus-secreting cells [NX]"	"Single Cell Type RNA - Muller glia cells [NX]"	"Single Cell Type RNA - Pancreatic endocrine cells [NX]"	"Single Cell Type RNA - Paneth cells [NX]"	"Single Cell Type RNA - Peritubular cells [NX]"	"Single Cell Type RNA - Proximal tubular cells [NX]"	"Single Cell Type RNA - Rod photoreceptor cells [NX]"	"Single Cell Type RNA - Sertoli cells [NX]"	"Single Cell Type RNA - Smooth muscle cells [NX]"	"Single Cell Type RNA - Spermatocytes [NX]"	"Single Cell Type RNA - Spermatogonia [NX]"	"Single Cell Type RNA - Suprabasal keratinocytes [NX]"	"Single Cell Type RNA - Syncytiotrophoblasts [NX]"	"Single Cell Type RNA - T-cells [NX]"	"Single Cell Type RNA - Undifferentiated cells [NX]"	"Single Cell Type RNA - Urothelial cells [NX]"
ABCB1	"ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1"	ENSG00000085563	"ATP binding cassette subfamily B member 1"	P08183	7	87503633-87713323	"Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Translocase	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 57.8;intestine: 49.6"	"Cell type enhanced"	"Detected in many"	13	"Cholangiocytes: 104.4;Enterocytes: 174.5;Paneth cells: 77.2"	"Cancer enhanced"	"Detected in many"		"renal cancer: 14.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 19.2"	"Group enriched"	"Detected in many"	8	"NK-cells: 11.4;T-cells: 19.2"	"Cell line enhanced"	"Detected in some"		"CACO-2: 30.1;HEK 293: 9.3;HEL: 16.7;Hep G2: 8.2;RPTEC TERT1: 11.5;SH-SY5Y: 36.8"									"CAB001716, HPA002199, HPA074614"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			"Nucleoplasm, Plasma membrane"	"Focal adhesion sites"	"CAB001716: , HPA002199: AB_1844428, HPA074614: "	"unprognostic (5.38e-3)"	"unprognostic (2.45e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.25e-2)"	"unprognostic (9.99e-5)"	"unprognostic (2.23e-3)"	"unprognostic (5.65e-3)"	"unprognostic (1.14e-1)"	"unprognostic (5.17e-2)"	"prognostic favorable (3.33e-4)"	"unprognostic (5.19e-1)"	"prognostic favorable (2.95e-4)"	"unprognostic (2.06e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.83e-1)"	"unprognostic (6.12e-2)"	2.6	57.8	9.4	3.2	11.5	1.2	3.4	5.1	10.5	5.5	22.7	3.8	2.0	14.4	9.4	3.5	2.0	3.2	9.0	1.8	9.2	6.6	19.1	15.6	3.8	2.2	9.4	5.7	2.2	1.5	1.7	1.3	3.1	11.1	2.7	10.7	7.6	1.5	2.1	1.1	1.3	49.6	5.7	9.0	2.4	1.7	1.3	8.6	0.1	2.4	1.4	2.2	2.6	5.9	1.9	0.0	0.1	0.0	11.4	19.2	1.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	30.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	9.3	16.7	1.9	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	11.5	0.1	0.4	36.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.9	0.0	0.4	3.2	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	7.8	0.0	19.2	0.4	2.0	4.7	0.0	1.9	1.2	4.8	0.1	11.4	0.0	0.0	0.0	1.5	9.4	11.5	5.1	10.5	9.2	6.6	9.4	5.7	11.1	8.6	0.0	4.8	5.9	0.1	0.7	0.6	2.8	104.4	1.4	1.2	47.1	0.0	5.0	5.0	10.2	21.6	23.1	174.5	23.3	1.6	0.1	0.5	0.1	3.5	32.6	0.4	0.0	0.0	3.7	1.2	2.5	0.9	0.8	0.0	0.0	8.9	0.0	11.4	77.2	0.0	44.0	0.9	0.0	0.8	0.5	0.4	0.5	8.2	27.3	1.7	0.1
ACTN1		ENSG00000072110	"Actinin alpha 1"	P12814	14	68874143-68979440	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Extravillous trophoblasts: 304.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 71.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004303, HPA006035"	Approved		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA		780000000	"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB004303: AB_626633, HPA006035: AB_1078095"	"unprognostic (4.40e-2)"	"unprognostic (1.03e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (2.49e-4)"	"unprognostic (6.19e-3)"	"prognostic unfavorable (7.63e-5)"	"unprognostic (3.62e-1)"	"unprognostic (3.23e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.71e-1)"	"prognostic unfavorable (9.08e-10)"	"unprognostic (2.87e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.05e-3)"	"prognostic unfavorable (8.00e-4)"	27.6	10.8	18.7	33.1	28.4	31.0	38.8	4.1	20.0	30.5	101.8	3.1	43.7	11.6	80.3	24.6	48.3	38.7	53.3	31.2	9.9	6.2	11.2	20.3	23.9	23.1	4.7	15.0	27.8	12.4	2.3	7.9	22.0	8.7	43.2	26.4	11.1	30.1	72.7	7.1	14.6	25.9	135.4	10.3	19.4	52.3	9.5	9.6	7.0	9.3	9.9	11.3	81.1	53.1	0.0	8.8	71.8	12.5	0.7	22.0	14.9	85.1	26.3	16.2	12.3	28.8	19.1	60.9	75.3	72.2	79.3	59.3	21.0	19.8	0.0	26.5	74.3	32.0	37.2	12.8	79.4	100.3	0.4	3.8	11.6	13.8	17.5	52.0	8.3	1.4	24.3	15.6	49.2	56.1	57.1	43.4	4.8	5.5	0.1	62.1	24.2	0.9	17.7	12.7	21.5	20.1	5.8	30.2	3.2	30.2	22.5	5.8	7.0	65.4	9.9	18.2	51.2	14.8	16.9	54.7	112.7	44.9	13.0	65.5	11.7	4.5	0.3	32.6	11.5	59.2	11.2	12.5	25.6	1.1	5.7	1.4	0.0	4.6	2.5	8.8	0.0	22.0	18.7	71.8	0.7	1.6	0.4	1.8	14.9	18.7	28.4	4.1	20.0	9.9	6.2	4.7	15.0	8.7	9.6	35.7	33.8	3.4	113.1	106.0	70.3	54.6	48.4	36.1	29.6	40.1	231.7	130.6	3.3	153.8	29.8	133.1	4.5	46.7	126.5	304.9	96.9	72.4	7.0	87.3	76.3	17.5	37.0	130.8	82.0	7.0	33.1	65.6	28.7	116.4	48.6	4.7	162.5	31.6	230.9	6.3	85.7	174.6	230.4	9.7	11.7	52.2	56.0	17.5	44.3	58.4
ACTR10	"ACTR11, Arp10, Arp11, HARP11"	ENSG00000131966	"Actin related protein 10 homolog"	Q9NZ32	14	58200080-58235636	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA000699			Approved	"Vesicles,Plasma membrane,Focal adhesion sites"		NA	NA			"Vesicles, Plasma membrane, Focal adhesion sites"		"HPA000699: "	"prognostic unfavorable (3.24e-4)"	"unprognostic (4.61e-2)"	"unprognostic (6.22e-3)"	"unprognostic (2.03e-2)"	"unprognostic (4.42e-1)"	"unprognostic (1.36e-2)"	"prognostic unfavorable (2.71e-5)"	"unprognostic (3.20e-1)"	"unprognostic (9.30e-2)"	"unprognostic (1.53e-1)"	"unprognostic (4.86e-1)"	"unprognostic (2.36e-1)"	"prognostic favorable (8.48e-8)"	"unprognostic (1.01e-2)"	"unprognostic (2.39e-1)"	"unprognostic (2.43e-2)"	"unprognostic (8.48e-2)"	31.5	22.8	23.8	12.5	27.2	15.8	23.4	16.2	32.3	16.4	23.3	13.6	16.1	10.1	18.2	18.3	18.3	17.6	14.8	27.3	21.8	28.4	20.5	15.4	17.7	16.7	32.5	26.7	19.4	18.5	19.2	18.9	21.3	33.7	22.2	15.2	14.6	35.8	17.6	21.4	26.4	12.8	21.0	18.5	17.5	14.1	13.8	9.7	14.6	18.2	13.2	14.4	13.7	16.3	7.4	5.9	15.8	9.8	7.2	12.0	5.1	3.4	1.9	3.9	1.6	13.4	6.5	2.0	2.7	3.1	4.5	5.3	2.9	4.0	5.1	3.9	5.7	2.5	3.5	5.1	4.0	6.1	2.8	12.9	2.0	3.7	5.5	11.4	3.5	3.0	8.3	5.9	3.8	7.5	3.7	5.8	3.1	1.6	4.2	8.4	9.4	4.7	13.2	2.0	3.3	18.0	3.2	6.9	3.1	7.9	4.4	2.2	2.5	5.2	4.1	12.7	4.7	7.2	6.0	4.9	4.6	9.4	4.2	2.3	2.4	1.5	5.4	5.0	2.8	2.6	15.8	7.3	10.3	8.4	8.9	12.0	7.4	9.6	8.2	5.3	5.6	10.0	10.2	9.9	7.2	9.8	5.9	6.7	5.1	23.8	27.2	16.2	32.3	21.8	28.4	32.5	26.7	33.7	9.7	56.6	43.6	39.5	61.8	47.4	67.4	72.6	38.2	44.2	33.0	48.8	27.5	94.0	106.1	72.0	6.3	50.9	47.7	46.7	52.4	64.0	71.0	55.6	42.7	28.7	68.6	54.0	32.2	47.3	34.9	8.2	81.7	44.1	70.9	56.9	42.7	84.3	64.7	24.6	75.3	91.6	58.2	77.6	61.8	118.4	56.8	56.2	130.4	42.6	34.0	48.5
AFAP1	"AFAP, AFAP-110"	ENSG00000196526	"Actin filament associated protein 1"	Q8N556	4	7758714-7939926	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"Early spermatids: 151.9;Extravillous trophoblasts: 100.0;Late spermatids: 257.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"eosinophil: 6.0"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.0;T-cells: 2.9"	"Cell line enhanced"	"Detected in many"		"TIME: 41.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA015642, CAB024712"	Enhanced		Supported	"Actin filaments,Focal adhesion sites,Cytosol"		NA	NA			"Actin filaments, Cytosol"	"Focal adhesion sites"	"CAB024712: , HPA015642: AB_1844632"	"unprognostic (1.12e-1)"	"unprognostic (2.78e-2)"	"unprognostic (3.97e-1)"	"unprognostic (7.29e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.93e-1)"	"unprognostic (3.30e-1)"	"prognostic unfavorable (2.84e-4)"	"unprognostic (2.00e-1)"	"unprognostic (3.39e-2)"	"unprognostic (3.40e-2)"	"unprognostic (1.38e-1)"	"prognostic unfavorable (8.18e-4)"	"unprognostic (1.40e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.85e-1)"	"unprognostic (2.44e-2)"	14.0	3.9	9.5	11.6	10.2	1.0	15.8	10.3	12.2	11.0	17.8	4.4	6.5	6.7	18.7	6.6	13.1	9.0	14.7	11.0	7.1	5.8	5.2	1.8	8.7	5.3	4.7	6.9	12.1	6.6	31.9	13.0	14.4	5.6	10.3	11.7	12.4	9.6	12.7	5.7	5.8	8.8	32.1	8.3	4.6	8.4	21.7	3.2	3.3	8.6	5.6	6.1	16.2	13.1	0.0	0.0	6.0	0.9	0.0	2.9	1.5	10.1	7.6	5.4	4.3	5.3	9.6	7.2	15.2	22.6	14.7	13.6	2.4	2.4	0.0	5.1	24.7	24.4	4.9	2.8	6.1	9.7	0.2	1.9	0.0	11.0	1.4	14.8	0.0	0.1	5.9	4.6	18.3	12.0	24.4	17.6	1.5	0.2	2.2	7.6	3.3	0.1	0.0	2.3	4.3	14.7	0.0	4.0	0.5	1.6	1.3	10.7	17.9	5.2	3.6	4.1	7.5	1.3	0.1	41.6	18.0	4.0	23.3	7.4	0.0	0.0	0.0	6.4	0.0	20.5	0.0	0.9	6.0	1.1	0.2	1.4	0.0	1.6	1.5	0.0	0.0	2.9	1.3	2.3	0.0	0.1	0.0	1.3	1.5	9.5	10.2	10.3	10.8	7.1	5.8	4.7	6.9	5.6	3.2	6.0	1.3	0.0	7.2	2.6	1.0	4.9	17.8	5.3	9.1	10.4	3.9	4.5	0.0	16.4	151.9	13.7	8.0	0.0	6.7	100.0	15.5	12.1	0.0	0.0	6.9	0.0	13.9	16.5	0.3	257.9	10.3	0.0	1.7	1.0	19.4	9.1	19.5	5.8	11.7	2.6	0.4	6.5	10.3	11.4	8.8	3.8	7.3	3.2	12.4	8.9
ARMC5	FLJ13063	ENSG00000140691	"Armadillo repeat containing 5"	Q96C12	16	31458080-31467166	"Disease related genes, Predicted intracellular proteins"			"Cushing syndrome, Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Hepatocytes: 23.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NB-4: 35.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041524, HPA063706"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"	"Intracellular and membrane"	NA	NA			"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA041524: AB_10796676, HPA063706: AB_2685098"	"unprognostic (1.37e-1)"	"unprognostic (1.68e-3)"	"unprognostic (8.22e-3)"	"unprognostic (9.96e-2)"	"unprognostic (2.59e-1)"	"unprognostic (2.94e-3)"	"unprognostic (4.09e-2)"	"unprognostic (6.14e-3)"	"unprognostic (2.37e-1)"	"unprognostic (1.11e-1)"	"prognostic favorable (1.97e-6)"	"unprognostic (4.70e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.99e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.45e-1)"	8.3	8.1	6.6	8.1	11.6	35.3	8.4	13.1	13.6	5.3	5.7	7.8	5.5	9.7	9.1	6.0	8.4	7.1	4.9	6.6	8.4	7.5	6.7	16.1	8.4	7.3	8.9	5.4	8.6	9.3	9.2	9.4	7.3	9.1	7.2	2.9	6.5	10.4	5.8	14.2	13.2	8.3	4.5	5.9	8.6	8.0	6.0	8.9	6.8	9.9	6.8	5.3	5.1	16.8	4.0	10.0	2.8	3.1	9.8	4.9	3.2	2.9	4.7	2.1	3.0	1.3	1.0	5.3	3.9	1.7	2.3	1.9	4.4	3.1	2.9	8.2	2.2	2.3	4.5	2.4	3.5	0.4	4.1	6.0	1.3	7.1	10.1	2.5	8.8	8.9	2.4	4.0	2.3	0.6	2.6	3.5	4.9	6.5	7.1	1.6	7.4	3.3	35.4	3.3	1.3	3.0	5.9	3.0	10.8	1.7	3.5	6.7	5.9	3.6	4.9	2.7	1.3	3.2	10.5	6.5	5.0	3.7	2.0	3.2	6.5	5.6	1.8	3.3	7.4	3.5	2.8	3.1	0.9	4.9	1.6	4.1	4.0	3.8	3.8	4.1	3.5	3.4	3.8	1.8	9.8	1.7	10.0	4.6	3.2	6.6	11.6	13.1	13.6	8.4	7.5	8.9	5.4	9.1	8.9	6.0	14.7	4.5	7.9	5.8	3.9	5.6	10.2	1.4	7.9	0.0	5.9	6.2	3.3	4.7	1.0	8.5	10.3	0.0	4.0	4.6	5.8	5.6	9.2	23.6	5.3	12.7	7.5	6.2	4.8	0.0	4.0	3.0	1.7	2.8	5.2	6.8	3.3	3.6	5.3	3.7	5.2	0.0	6.4	3.9	6.1	5.5	9.6	5.0	3.8	4.8
ASCC2	"ASC1p100, DKFZp586O0223, FLJ21588"	ENSG00000100325	"Activating signal cointegrator 1 complex subunit 2"	Q9H1I8	22	29788608-29838304	"Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Late spermatids: 128.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001439, HPA052879"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA			"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA001439: AB_1078229, HPA052879: AB_2732577"	"unprognostic (1.70e-1)"	"unprognostic (1.02e-2)"	"unprognostic (8.58e-2)"	"unprognostic (3.83e-3)"	"unprognostic (1.84e-1)"	"unprognostic (2.45e-3)"	"unprognostic (3.01e-3)"	"unprognostic (1.16e-1)"	"unprognostic (1.35e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.97e-3)"	"unprognostic (5.19e-2)"	"unprognostic (7.53e-2)"	"unprognostic (3.81e-1)"	"unprognostic (2.05e-3)"	19.5	24.2	13.1	22.1	15.1	32.3	23.1	13.4	14.0	16.8	16.9	17.9	22.5	16.5	17.1	17.7	31.1	14.6	19.0	17.7	10.8	8.2	15.8	35.3	19.2	20.2	15.4	9.1	16.2	18.4	17.5	20.6	23.2	12.5	20.1	17.8	17.6	22.2	30.9	50.0	21.7	22.3	14.2	12.9	22.7	25.8	41.0	13.0	28.9	21.9	25.0	26.6	19.1	21.2	11.3	21.1	28.5	27.6	17.3	18.8	10.9	19.7	11.5	12.5	16.9	18.8	16.7	18.0	20.6	15.9	21.4	21.5	13.4	10.7	19.7	14.9	19.8	13.6	24.0	16.0	23.4	18.1	25.2	28.0	16.9	14.6	16.0	23.6	30.3	51.5	17.9	21.3	24.3	22.4	12.6	18.7	13.3	17.4	19.2	19.3	24.4	18.5	16.0	9.1	27.9	15.7	22.4	15.4	20.6	13.1	32.7	19.4	17.1	19.1	21.1	15.3	13.4	15.0	15.9	18.4	30.0	5.1	18.1	20.3	23.0	17.5	23.4	17.5	17.0	21.6	18.2	16.7	28.5	18.8	27.6	16.8	11.3	14.2	15.8	21.1	8.9	14.7	14.8	5.1	17.3	22.5	12.0	16.4	10.9	13.1	15.1	13.4	14.0	10.8	8.2	15.4	9.1	12.5	13.0	17.9	14.3	24.0	18.4	26.7	9.0	16.5	25.5	18.7	18.2	38.4	3.9	37.6	10.0	24.0	92.7	20.5	38.5	23.3	21.6	52.8	23.3	15.9	34.6	23.2	27.5	4.8	14.9	17.8	24.8	128.4	28.7	33.0	27.0	22.6	17.2	11.8	22.4	24.6	23.3	15.2	13.6	19.4	16.0	39.1	19.2	34.4	37.1	35.9	20.3	30.8
C11orf96	AG2	ENSG00000187479	"Chromosome 11 open reading frame 96"		11	43942505-43944338	"Predicted intracellular proteins"				"Evidence at transcript level"	"Evidence at transcript level"				"Tissue enhanced"	"Detected in many"		"ovary: 152.0"	"Cell type enhanced"	"Detected in many"	19	"Peritubular cells: 445.9;Sertoli cells: 297.5;Smooth muscle cells: 1129.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"SH-SY5Y: 65.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038843	Uncertain		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"		No	NA			"Nucleoplasm, Focal adhesion sites, Cytosol"		"HPA038843: AB_10673296"	"unprognostic (1.55e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.28e-2)"	"unprognostic (8.15e-3)"	"unprognostic (5.49e-2)"	"unprognostic (3.42e-3)"	"unprognostic (8.11e-3)"	"unprognostic (1.15e-2)"	"unprognostic (2.46e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.01e-1)"	"unprognostic (5.98e-2)"	"prognostic unfavorable (2.34e-5)"	"unprognostic (2.65e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.18e-2)"	"unprognostic (3.19e-2)"	68.2	81.2	4.9	23.4	17.4	3.4	42.6	2.6	10.5	39.7	32.2	3.3	6.6	12.4	35.1	41.5	16.3	69.3	70.0	34.3	8.8	7.9	17.9	67.7	61.9	4.9	7.6	4.7	152.0	18.1	3.8	14.2	14.6	32.8	28.6	6.2	7.6	2.3	12.8	38.2	10.1	17.2	22.9	15.3	12.7	31.3	41.7	4.2	0.0	16.7	14.0	2.3	62.9	32.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.7	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.7	0.0	0.1	0.0	0.0	0.0	0.9	2.0	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.4	0.0	0.0	0.4	0.6	0.7	0.0	0.0	0.0	0.7	0.8	0.5	0.0	0.3	3.3	0.2	1.4	0.0	0.0	0.7	65.3	0.0	0.0	6.0	1.9	0.0	0.7	0.9	3.1	1.3	0.8	0.0	7.6	0.0	1.0	2.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	17.4	2.6	7.1	8.8	7.9	7.6	4.7	32.8	4.2	6.0	166.6	0.0	14.6	82.5	15.3	5.3	0.0	1.4	2.3	0.0	2.0	1.1	0.0	2.2	3.5	30.5	0.0	0.0	0.5	3.5	142.9	42.4	12.8	2.5	3.3	1.6	0.0	114.8	6.9	5.8	199.6	9.5	165.4	0.0	0.0	2.3	2.8	0.0	445.9	0.0	7.6	297.5	1129.9	1.6	1.4	77.3	2.6	2.5	0.0	35.8
CNTD1	"CNTD, FLJ40137"	ENSG00000176563	"Cyclin N-terminal domain containing 1"	Q8N815	17	42798792-42811587	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	11	"testis: 31.0"	"Group enriched"	"Detected in many"	12	"Ciliated cells: 80.3;Early spermatids: 53.3;Late spermatids: 75.8;Spermatocytes: 135.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.7"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"A-431: 6.3;ASC diff: 4.3;SiHa: 3.3;T-47d: 2.4"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA023324			Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"HPA023324: AB_1848931"	"unprognostic (5.92e-2)"	"unprognostic (1.99e-3)"	"unprognostic (3.66e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.25e-1)"	"unprognostic (6.29e-3)"	"unprognostic (6.61e-2)"	"unprognostic (1.09e-2)"	"unprognostic (7.82e-2)"	"unprognostic (6.18e-2)"	"unprognostic (1.36e-2)"	"unprognostic (2.07e-1)"	"unprognostic (5.89e-7)"	"unprognostic (1.52e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.81e-4)"	0.2	0.1	0.7	0.0	1.4	0.0	1.6	0.2	1.7	0.2	0.6	0.4	0.0	0.0	0.1	0.9	0.1	0.5	0.0	0.1	1.5	0.3	1.2	0.1	0.3	0.0	0.5	0.8	0.3	0.8	0.0	0.1	0.0	0.9	1.1	1.5	0.1	0.5	0.0	0.2	0.1	0.2	0.7	0.8	0.1	2.3	31.0	1.6	0.0	0.1	0.0	0.0	0.2	0.1	0.9	0.1	2.7	0.3	0.1	0.3	0.3	6.3	0.7	0.5	1.3	4.3	1.5	0.0	0.0	0.3	0.4	1.4	0.0	0.0	0.0	0.2	1.2	0.0	0.0	0.0	0.0	1.0	0.2	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.6	0.0	0.0	1.1	0.2	0.0	0.4	0.6	1.3	0.0	0.0	0.2	0.6	0.0	0.2	0.0	0.2	0.0	0.4	0.7	0.0	0.0	0.0	3.3	0.3	0.8	0.1	2.4	0.0	0.0	1.4	0.2	0.0	0.0	0.0	0.3	0.1	0.1	0.5	0.4	0.0	0.3	0.0	0.3	0.2	0.3	0.4	0.1	0.0	0.1	0.9	0.0	0.0	2.7	0.1	0.1	0.0	0.0	0.3	0.7	1.4	0.2	1.7	1.5	0.3	0.5	0.8	0.9	1.6	3.0	2.9	0.0	0.4	0.3	1.6	0.8	0.0	80.3	3.4	0.0	0.0	0.2	5.0	0.2	53.3	0.3	0.5	0.0	0.3	0.3	0.6	7.4	5.8	0.9	0.3	6.4	0.0	0.0	1.0	75.8	2.3	0.7	0.0	0.0	4.6	1.2	0.3	0.0	1.1	0.3	0.4	6.5	0.9	135.1	2.7	0.5	0.2	0.5	2.1	0.9
DLGAP4	"DAP4, KIAA0964, SAPAP4"	ENSG00000080845	"DLG associated protein 4"	Q9Y2H0	20	36306336-36528637	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"U-138 MG: 64.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054105, HPA056378"	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA054105: AB_2682381, HPA056378: "	"unprognostic (1.11e-1)"	"unprognostic (1.42e-1)"	"unprognostic (9.00e-2)"	"prognostic unfavorable (2.24e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavorable (3.73e-6)"	"unprognostic (1.23e-1)"	"prognostic favorable (9.88e-5)"	"unprognostic (1.28e-1)"	"unprognostic (2.18e-2)"	"unprognostic (8.45e-2)"	"prognostic unfavorable (2.48e-4)"	"unprognostic (1.07e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.53e-1)"	18.8	16.6	25.7	14.3	32.9	4.5	18.0	16.2	31.9	19.0	20.1	9.0	14.9	13.5	23.1	13.1	16.8	18.5	17.0	25.9	23.7	12.7	10.2	11.0	21.6	9.8	9.5	20.7	18.9	30.2	7.7	10.2	16.9	8.8	15.7	10.1	15.4	19.3	21.2	58.0	27.1	13.6	27.2	6.8	14.5	12.2	12.6	10.9	8.3	13.8	16.8	10.8	29.0	15.0	16.1	13.5	19.5	13.1	6.9	12.5	9.1	14.1	12.9	15.8	13.0	15.0	24.6	15.9	21.4	19.6	21.0	14.6	19.4	9.1	4.0	11.6	30.0	18.6	13.7	4.2	21.9	15.7	6.4	1.5	9.1	6.6	13.1	21.7	3.6	7.9	16.2	17.0	24.8	17.4	16.3	20.6	5.7	6.3	11.0	15.8	10.6	7.4	13.9	6.8	10.4	27.6	7.4	4.2	5.5	9.8	7.0	10.4	14.3	14.0	28.5	17.6	16.8	16.3	6.4	20.7	64.1	19.5	27.5	11.7	3.8	2.7	4.3	25.6	4.6	25.1	2.1	12.8	19.5	12.5	13.1	9.8	16.1	11.3	8.7	11.3	14.9	8.8	7.0	18.5	6.9	12.6	13.5	8.7	9.1	25.7	32.9	16.2	31.9	23.7	12.7	9.5	20.7	8.8	10.9	14.9	18.6	15.9	41.2	59.0	31.9	25.0	25.5	17.4	13.6	12.2	7.9	19.6	6.6	45.3	63.3	34.3	19.2	0.0	47.9	41.6	32.7	58.9	11.6	16.3	24.9	69.9	60.7	24.5	18.1	119.1	27.6	21.1	10.1	63.1	29.8	36.4	66.0	24.6	24.8	16.3	27.9	71.1	41.0	13.6	16.2	62.7	46.1	15.0	16.9	46.3
EIF2B2	"EIF-2Bbeta, EIF2B"	ENSG00000119718	"Eukaryotic translation initiation factor 2B subunit beta"	P49770	14	75002911-75012366	"Disease related genes, Predicted intracellular proteins"	"Protein biosynthesis"	"Initiation factor"	"Disease mutation, Leukodystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Syncytiotrophoblasts: 138.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005841, CAB037105, HPA048028"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			"Plasma membrane, Focal adhesion sites"	Nucleoplasm	"CAB037105: AB_1840834, HPA005841: AB_1078725, HPA048028: AB_2680235"	"unprognostic (1.10e-1)"	"unprognostic (4.41e-2)"	"unprognostic (5.70e-2)"	"unprognostic (6.71e-2)"	"unprognostic (7.64e-2)"	"unprognostic (3.45e-3)"	"prognostic unfavorable (2.26e-6)"	"unprognostic (1.48e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.95e-2)"	"unprognostic (1.01e-1)"	"prognostic favorable (2.95e-4)"	"unprognostic (4.15e-2)"	"unprognostic (2.74e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.28e-2)"	11.8	20.1	11.6	9.2	12.3	9.1	11.6	11.0	16.4	13.2	13.9	13.2	9.2	9.8	11.6	15.8	14.3	10.4	12.6	15.0	11.5	12.0	19.6	18.8	10.3	11.6	13.6	11.4	12.3	12.9	32.3	11.9	20.4	15.7	13.6	12.2	11.7	11.1	14.8	29.0	12.5	13.1	11.0	14.8	12.1	10.9	20.1	11.0	17.7	33.4	11.2	12.7	14.9	9.7	4.2	5.1	7.7	3.9	6.5	8.1	4.8	5.1	6.3	5.1	5.8	5.9	4.9	6.8	3.3	5.5	6.5	7.6	7.9	5.3	4.6	2.1	5.2	4.1	3.9	7.9	7.7	9.8	2.8	5.9	4.0	5.5	5.4	7.7	3.0	4.8	4.5	7.4	8.3	8.6	5.6	22.3	4.0	3.6	4.5	13.9	15.2	4.7	3.7	3.6	6.4	9.3	3.0	6.0	3.8	9.2	6.2	5.5	4.4	3.5	5.0	7.4	6.6	8.1	2.8	5.7	5.0	4.9	2.2	4.2	7.7	6.3	5.4	5.5	3.7	3.8	7.7	3.9	2.8	6.7	3.9	5.6	4.2	5.9	5.4	5.1	4.1	4.4	4.6	2.2	6.5	3.7	4.2	8.1	4.8	11.6	12.3	11.0	16.4	11.5	12.0	13.6	11.4	15.7	11.0	17.9	8.6	15.1	16.5	15.8	25.7	16.1	28.1	10.7	14.8	24.4	43.2	42.7	34.9	31.8	7.6	18.8	14.3	0.0	28.8	47.0	15.5	14.3	20.8	10.5	29.7	27.0	15.0	12.9	16.5	7.8	14.7	14.0	13.5	34.3	9.1	24.2	26.4	12.4	15.2	35.2	27.5	25.8	21.2	39.0	22.8	19.2	138.4	13.8	17.8	15.9
ENAH	"FLJ10773, MENA, NDPP1"	ENSG00000154380	"ENAH, actin regulator"	Q8N8S7	1	225486835-225653142	"Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"EFO-21: 61.0"	"Low region specificity"	"Detected in all"							"HPA028448, HPA028696"	Enhanced		Enhanced	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA		18000	"Plasma membrane, Focal adhesion sites, Cytosol"		"HPA028448: AB_10600766, HPA028696: AB_10611249"	"unprognostic (2.56e-2)"	"unprognostic (8.03e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.35e-2)"	"unprognostic (5.61e-3)"	"unprognostic (2.85e-1)"	"unprognostic (1.21e-3)"	"unprognostic (2.30e-1)"	"unprognostic (2.23e-1)"	"unprognostic (9.22e-2)"	"unprognostic (4.71e-3)"	"unprognostic (2.14e-1)"	"unprognostic (2.24e-3)"	"unprognostic (8.84e-2)"	"unprognostic (5.83e-2)"	"unprognostic (7.92e-2)"	"unprognostic (2.93e-2)"	19.2	17.4	15.8	11.9	17.0	0.6	11.1	7.6	17.6	17.8	24.4	15.3	39.9	9.3	21.9	19.9	16.7	11.8	29.0	18.2	16.7	15.3	5.8	5.9	13.8	3.5	13.7	11.3	24.3	16.7	22.5	10.3	13.5	12.7	26.4	8.0	3.3	14.5	44.9	20.2	8.2	8.0	61.4	13.4	17.3	21.0	18.5	17.2	5.3	6.8	11.4	3.5	35.3	21.9	2.1	0.4	1.0	0.3	0.5	0.4	0.0	20.5	16.5	20.5	18.5	8.0	10.6	26.4	22.9	11.0	13.8	10.5	10.6	7.6	8.7	61.0	35.3	12.4	18.2	23.9	8.6	13.2	0.1	14.8	9.1	14.7	14.2	24.0	1.0	0.3	16.3	10.4	17.9	22.9	11.3	10.9	2.5	0.6	0.4	13.6	4.0	4.1	1.0	34.5	5.4	15.0	6.2	28.9	0.2	6.3	15.9	20.2	16.3	44.9	17.2	15.1	16.3	20.4	1.3	21.2	35.9	26.4	29.8	45.3	1.0	2.5	5.9	19.7	1.1	18.3	1.0	0.3	0.2	0.4	0.1	0.3	0.6	0.4	0.3	0.0	2.1	0.4	0.4	1.0	0.5	0.2	0.4	0.2	0.0	15.8	17.0	7.6	13.7	16.7	15.3	13.7	11.3	12.7	17.2	11.9	31.2	2.2	136.9	114.6	7.8	109.0	56.0	123.1	56.9	21.0	58.9	50.3	3.3	71.8	67.2	59.1	5.1	0.0	86.5	13.1	84.6	122.2	4.7	9.6	9.4	15.9	39.7	22.1	1.8	19.9	53.8	7.0	79.2	5.4	28.6	30.0	72.6	14.4	158.7	10.5	19.1	90.5	115.4	8.0	40.0	117.2	50.6	0.0	23.0	87.2
EVI2B	"CD361, D17S376, EVDB"	ENSG00000185862	"Ecotropic viral integration site 2B"	P34910	17	31303766-31314112	"CD markers, Predicted membrane proteins"			Proto-oncogene	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 133.6;lymphoid tissue: 72.8"	"Cell type enhanced"	"Detected in many"	16	"B-cells: 217.4;Kupffer cells: 447.5;Macrophages: 274.7;T-cells: 178.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 133.6"	"Group enriched"	"Detected in all"	4	"granulocytes: 133.6;monocytes: 34.3"	"Cell line enhanced"	"Detected in many"		"Daudi: 24.2;HHSteC: 19.9;HL-60: 27.3;HMC-1: 38.5;Karpas-707: 27.3;NB-4: 21.6;RPMI-8226: 39.9;THP-1: 34.4"					"Low region specificity"	"Detected in all"			HPA007436	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"HPA007436: AB_1848307"	"unprognostic (1.07e-2)"	"unprognostic (1.20e-2)"	"unprognostic (5.97e-2)"	"unprognostic (4.09e-3)"	"unprognostic (2.99e-2)"	"unprognostic (1.41e-2)"	"unprognostic (3.06e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.78e-2)"	"unprognostic (2.34e-1)"	"prognostic unfavorable (2.05e-4)"	"unprognostic (1.56e-2)"	"unprognostic (3.32e-2)"	"unprognostic (8.64e-2)"	"unprognostic (2.73e-2)"	15.0	3.6	4.4	37.7	5.8	44.0	4.2	1.7	4.4	3.7	10.7	6.5	0.3	6.0	2.8	4.8	7.1	4.7	8.1	6.7	6.4	4.4	7.8	7.1	38.5	37.5	10.2	2.6	3.8	2.7	0.4	2.1	4.8	7.8	5.3	8.1	2.5	6.6	1.5	2.3	2.4	23.3	4.2	22.0	72.8	8.0	3.7	6.7	26.1	4.0	3.0	43.0	13.0	7.6	18.6	14.6	133.6	34.3	4.1	16.4	19.8	0.1	0.1	0.0	0.0	1.9	2.5	0.0	0.2	1.7	2.0	3.7	0.0	0.9	24.2	0.0	1.5	7.5	0.1	0.0	0.3	2.2	0.0	0.0	0.5	0.0	0.0	19.9	27.3	38.5	4.6	0.0	1.1	1.5	0.6	1.9	2.0	0.3	27.3	5.7	0.0	7.9	21.6	0.0	0.0	0.0	13.9	0.1	39.9	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	34.4	2.1	0.5	0.0	0.2	1.9	5.3	0.2	5.3	2.5	9.4	0.6	78.9	30.5	74.5	8.2	23.2	7.9	18.6	12.6	10.6	14.6	14.3	9.7	9.1	133.6	4.1	34.3	8.4	16.4	19.8	4.4	5.8	1.7	4.4	6.4	4.4	10.2	2.6	7.8	6.7	0.0	17.9	217.4	0.6	4.7	0.2	0.4	2.5	4.0	11.4	1.8	0.0	0.5	0.0	0.0	5.3	2.7	0.2	0.0	0.0	0.5	2.8	0.3	78.7	1.7	88.8	0.0	0.0	9.8	447.5	4.7	0.0	274.7	35.4	10.8	0.0	0.0	0.7	0.0	0.4	0.7	0.8	19.4	4.1	0.3	0.5	3.1	0.2	178.5	0.0	1.1
FABP3	"FABP11, H-FABP, MDGI, O-FABP"	ENSG00000121769	"Fatty acid binding protein 3"	P05413	1	31365625-31376850	"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"heart muscle: 420.9;skeletal muscle: 129.4"	"Cell type enriched"	"Detected in many"	6	"Cardiomyocytes: 2447.6"	"Cancer enhanced"	"Detected in all"		"renal cancer: 92.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	5	"ASC TERT1: 120.7"	"Low region specificity"	"Detected in all"							"CAB017830, HPA055754"	Enhanced		Uncertain	"Golgi apparatus,Plasma membrane,Focal adhesion sites"		NA	NA	1640000	4400000	"Focal adhesion sites"	"Golgi apparatus, Plasma membrane"	"CAB017830: , HPA055754: AB_2682909"	"unprognostic (2.07e-2)"	"unprognostic (2.50e-2)"	"unprognostic (1.32e-3)"	"unprognostic (1.73e-2)"	"unprognostic (2.05e-1)"	"unprognostic (1.62e-1)"	"unprognostic (6.07e-3)"	"unprognostic (1.04e-1)"	"unprognostic (6.86e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.85e-1)"	"unprognostic (1.67e-1)"	"prognostic favorable (1.54e-7)"	"unprognostic (5.80e-3)"	"unprognostic (3.45e-1)"	"unprognostic (7.38e-3)"	"unprognostic (9.76e-3)"	2.3	5.2	8.1	0.7	6.0	0.5	22.7	1.4	14.6	3.9	1.3	0.8	3.4	0.7	6.8	5.3	3.1	2.8	1.1	420.9	11.0	5.3	21.3	1.9	4.3	1.3	9.8	6.0	2.2	0.4	0.3	0.7	1.1	13.7	5.0	1.5	3.0	4.4	14.0	129.4	0.9	0.6	13.0	3.4	3.9	3.6	2.0	1.3	0.1	1.7	31.6	2.2	2.5	2.5	1.4	0.5	0.0	0.9	0.2	0.9	0.6	0.1	0.0	3.3	0.2	23.1	120.7	1.1	0.9	8.9	0.1	3.2	0.2	0.9	0.2	12.8	2.5	0.0	0.3	0.9	0.0	0.1	0.1	0.5	0.4	1.1	2.4	1.5	0.2	0.0	10.7	0.0	2.4	0.0	0.3	0.0	0.1	0.2	0.0	1.1	0.0	0.0	0.2	6.1	0.0	0.4	0.1	1.2	0.0	2.9	0.0	0.3	0.0	0.5	0.0	13.9	7.1	0.1	1.4	0.3	0.2	0.1	2.1	0.2	0.1	0.4	0.1	0.5	0.1	0.3	0.0	0.4	0.0	0.9	0.9	0.6	0.2	0.5	0.5	0.5	1.4	0.0	0.9	0.0	0.2	0.1	0.4	0.6	0.6	8.1	6.0	1.4	13.3	11.0	5.3	9.8	6.0	13.7	1.3	0.0	1.7	0.8	1.0	3.2	3.1	2447.6	5.1	2.7	2.3	26.2	2.0	2.1	383.0	0.3	2.1	0.8	0.0	0.0	0.3	1.3	14.9	3.8	1.1	0.0	96.1	7.9	0.0	3.7	20.0	4.2	6.4	17.6	8.5	0.0	0.0	2.7	0.5	3.6	7.4	399.5	8.1	0.0	32.3	0.3	0.1	2.6	1.4	1.0	0.1	5.2
FBLIM1	"CAL, FBLP-1, migfilin"	ENSG00000162458	"Filamin binding LIM protein 1"	Q8WUP2	1	15756607-15786594	"Predicted intracellular proteins"	"Cell adhesion, Cell shape"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Peritubular cells: 180.0;Sertoli cells: 142.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HUVEC TERT2: 54.1;TIME: 84.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA025287, HPA072750"	Approved		Enhanced	"Nucleoli fibrillar center,Cell Junctions,Focal adhesion sites"		NA	NA			"Cell Junctions, Focal adhesion sites"	"Nucleoli fibrillar center"	"HPA025287: AB_1848443, HPA072750: AB_2686554"	"unprognostic (4.10e-2)"	"prognostic unfavorable (4.07e-4)"	"unprognostic (2.26e-1)"	"unprognostic (5.33e-2)"	"unprognostic (2.46e-2)"	"unprognostic (1.52e-1)"	"unprognostic (9.33e-2)"	"unprognostic (8.77e-3)"	"prognostic unfavorable (6.15e-4)"	"unprognostic (2.02e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.09e-1)"	"prognostic unfavorable (8.64e-4)"	"unprognostic (8.33e-2)"	"unprognostic (3.01e-1)"	"unprognostic (1.08e-1)"	"unprognostic (8.21e-2)"	11.6	6.0	1.7	12.8	1.4	0.0	10.1	0.8	1.3	21.5	36.6	1.4	26.8	24.6	30.3	15.8	17.8	16.5	60.2	21.7	1.2	1.0	18.2	3.0	14.7	16.1	1.8	1.6	36.0	13.0	13.9	3.8	21.5	2.3	26.7	15.7	9.0	13.0	26.5	4.1	6.2	62.8	18.7	1.3	22.7	18.9	22.3	0.9	1.3	10.3	7.4	6.3	24.7	16.9	1.8	1.3	4.6	1.2	1.6	1.2	0.3	6.5	3.7	3.3	0.1	0.8	1.7	4.5	11.2	17.9	8.3	6.7	1.2	9.9	0.0	24.3	18.0	14.4	12.7	2.4	25.7	4.1	0.0	1.2	0.0	0.9	6.3	21.6	0.0	0.1	8.5	17.2	6.9	16.5	17.2	54.1	0.4	0.2	1.6	2.8	0.1	0.1	0.1	3.4	10.3	4.8	0.0	0.0	0.2	10.4	4.5	0.0	8.0	5.9	0.7	1.3	7.2	1.4	0.1	84.4	11.0	1.5	0.1	5.1	0.1	0.2	0.1	1.6	0.0	0.1	4.6	1.2	1.0	0.7	0.5	0.6	1.0	0.7	0.7	0.4	1.8	1.1	1.2	3.5	1.6	0.7	1.3	0.4	0.3	1.7	1.4	0.8	1.3	1.2	1.0	1.8	1.6	2.3	0.9	11.9	21.5	5.2	54.8	76.6	3.5	30.9	45.9	12.0	29.6	15.7	5.9	5.8	0.0	80.2	2.4	18.4	138.3	0.0	46.9	102.1	26.9	24.2	17.4	1.8	5.3	1.6	44.1	38.1	0.6	1.8	74.2	10.4	13.5	3.6	47.1	10.0	88.8	84.2	180.0	1.2	5.1	142.3	66.2	2.3	1.8	54.8	16.2	6.1	40.4	47.2
FCMR	"FAIM3, TOSO"	ENSG00000162894	"Fc fragment of IgM receptor"	O60667	1	206904386-206923247	"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 99.6;intestine: 30.1;lymphoid tissue: 84.9"	"Group enriched"	"Detected in many"	11	"B-cells: 125.3;T-cells: 41.7"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"B-cells: 99.6;T-cells: 60.0"	"Group enriched"	"Detected in some"	5	"RPMI-8226: 53.0;U-266/70: 26.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA003910	Approved		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"	"Secreted to blood"	NA	NA		2400000	"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA003910: AB_1078798"	"prognostic favorable (4.23e-4)"	"unprognostic (1.16e-3)"	"unprognostic (7.48e-2)"	"unprognostic (3.06e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.69e-3)"	"unprognostic (1.15e-1)"	"unprognostic (4.85e-3)"	"unprognostic (1.03e-1)"	"unprognostic (3.97e-1)"	"unprognostic (3.23e-2)"	"unprognostic (2.01e-1)"	"unprognostic (8.15e-3)"	"unprognostic (8.06e-2)"	"unprognostic (2.12e-2)"	"unprognostic (3.74e-2)"	"unprognostic (5.05e-3)"	15.5	0.6	0.5	42.9	0.5	2.9	1.5	0.4	0.4	0.8	2.5	0.4	0.3	1.2	1.2	0.8	3.4	1.3	2.6	1.0	0.5	0.5	2.4	1.5	3.9	77.2	0.5	0.0	1.3	0.7	0.0	0.9	0.8	0.2	1.4	2.3	1.3	10.1	0.3	1.9	0.6	30.1	0.4	0.6	78.8	2.8	0.5	0.0	51.8	1.8	1.2	84.9	8.5	1.2	99.6	1.4	5.3	0.4	18.4	60.0	28.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	1.9	0.1	0.1	0.0	0.0	3.4	0.0	0.1	0.3	0.1	0.0	0.4	0.2	0.0	0.1	0.0	0.4	0.0	0.8	0.0	0.0	0.0	0.3	0.1	0.6	0.0	0.0	2.7	0.0	7.4	0.0	0.1	1.0	0.1	0.0	0.0	0.0	1.7	0.2	53.0	0.0	0.1	0.0	0.0	1.0	0.2	5.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.0	26.7	1.9	7.4	0.3	0.0	0.2	0.5	0.2	0.2	20.3	0.4	26.4	80.3	28.1	26.2	0.2	99.6	49.5	33.3	5.3	18.4	0.3	1.4	60.0	28.2	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.0	0.2	0.0	0.0	4.6	125.3	3.9	0.0	0.0	3.0	7.6	1.4	2.3	0.0	0.0	0.0	0.0	1.3	0.1	0.1	0.0	0.0	2.6	0.1	0.6	2.6	0.0	1.1	3.8	0.0	0.0	5.5	5.1	0.0	0.3	1.2	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.3	0.0	0.0	0.3	0.1	1.0	0.0	0.0	41.7	1.2	7.1
FERMT2	"KIND2, mig-2, PLEKHC1, UNC112B"	ENSG00000073712	"Fermitin family member 2"	Q96AC1	14	52857268-52952435	"Predicted intracellular proteins"	"Cell adhesion, Cell shape, Wnt signaling pathway"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	12	"MAIT T-cell: 3.8"	"Lineage enriched"	"Detected in single"	39	"T-cells: 3.8"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA040505, HPA072965"	Uncertain		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA		58000	"Focal adhesion sites"	"Nucleoplasm, Cytosol"	"HPA040505: AB_10673300, HPA072965: "	"unprognostic (4.38e-2)"	"unprognostic (4.25e-2)"	"unprognostic (8.00e-3)"	"unprognostic (2.42e-2)"	"unprognostic (2.51e-2)"	"unprognostic (4.89e-3)"	"unprognostic (2.50e-2)"	"unprognostic (1.92e-1)"	"unprognostic (4.21e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.58e-1)"	"unprognostic (1.99e-1)"	"unprognostic (3.87e-2)"	"unprognostic (3.96e-3)"	"unprognostic (7.69e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.73e-3)"	45.9	7.2	15.5	12.3	14.3	0.1	24.4	7.9	12.8	24.1	36.6	12.7	16.0	4.2	41.6	14.2	20.6	22.2	22.2	21.8	18.3	7.5	18.4	35.3	18.1	5.4	15.0	9.1	23.3	6.7	5.8	7.2	37.9	10.7	24.1	11.5	11.0	7.1	41.3	14.5	5.0	11.0	56.7	12.9	11.7	21.4	10.2	15.5	0.6	13.3	6.2	2.1	49.5	16.5	0.0	0.0	0.0	0.0	0.0	3.8	0.0	4.8	4.3	22.8	10.4	37.3	30.7	19.0	32.6	21.1	38.8	24.5	7.3	3.9	0.0	11.1	33.3	7.6	2.1	17.7	2.4	29.2	0.0	4.9	6.8	19.5	8.6	47.9	0.1	2.8	29.5	5.2	21.3	28.3	17.7	20.0	3.7	0.1	34.4	29.0	5.9	1.6	0.1	14.4	0.0	11.3	0.8	23.2	0.0	13.6	4.5	1.4	29.3	34.5	7.7	8.0	24.2	6.7	0.2	25.0	30.6	21.0	24.3	12.0	5.1	6.1	0.1	7.0	0.0	7.3	0.0	0.0	0.0	0.1	0.0	3.8	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.5	14.3	7.9	12.4	18.3	7.5	15.0	9.1	10.7	15.5	71.5	50.2	0.0	111.7	16.6	32.8	53.2	20.4	14.7	37.5	38.4	35.3	69.7	26.6	48.1	59.4	87.9	0.0	0.0	28.6	138.3	102.2	34.3	56.6	71.6	9.0	14.3	0.0	120.9	9.2	20.6	69.3	6.2	43.9	8.2	0.0	57.0	23.6	0.0	164.4	37.4	57.4	148.8	146.8	3.4	10.0	7.0	85.8	4.3	0.0	35.6
GAS7	"KIAA0394, MGC1348"	ENSG00000007237	"Growth arrest specific 7"	O60861	17	9910609-10198551	"Cancer-related genes, Disease related genes, Predicted intracellular proteins"	"Differentiation, Neurogenesis"	"Developmental protein"	"Cancer-related genes, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 86.2"	"Cell type enhanced"	"Detected in many"	6	"Early spermatids: 49.9;Kupffer cells: 62.0;Late spermatids: 52.5"	"Cancer enhanced"	"Detected in all"		"melanoma: 54.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 17.6"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	9	"WM-115: 110.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004838, HPA064678"	Enhanced		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Plasma membrane"	"Actin filaments, Focal adhesion sites"	"HPA004838: AB_2667263, HPA064678: AB_2685319"	"unprognostic (1.68e-2)"	"unprognostic (2.84e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.01e-2)"	"unprognostic (7.32e-2)"	"unprognostic (7.16e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.48e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.94e-3)"	"unprognostic (6.48e-2)"	"unprognostic (8.78e-2)"	"unprognostic (3.08e-2)"	"prognostic unfavorable (6.89e-4)"	19.1	6.5	22.1	15.4	40.3	18.7	10.8	86.2	64.7	22.6	9.3	33.4	1.7	5.2	9.7	4.4	17.0	12.6	11.5	23.1	25.8	15.0	1.5	2.1	9.9	5.9	28.1	25.0	5.9	2.8	1.4	1.7	11.0	14.2	3.7	8.7	7.7	4.0	8.2	3.9	21.2	7.4	16.3	33.8	10.0	4.2	11.8	22.2	2.7	2.5	2.7	7.2	11.7	7.8	0.4	3.6	11.0	17.6	2.8	2.1	4.4	0.0	0.1	0.1	0.2	3.4	4.9	0.0	0.1	0.0	0.5	0.2	0.0	0.0	1.3	0.4	1.3	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.3	0.1	1.1	0.3	10.1	0.9	0.0	1.0	0.0	0.0	0.0	8.7	0.0	0.1	0.0	0.0	10.7	3.2	0.5	0.4	0.0	2.8	0.0	9.8	0.0	0.0	0.0	0.6	0.0	0.0	12.7	4.7	0.5	5.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	7.1	110.2	0.4	17.6	10.8	2.1	4.7	0.7	0.3	0.2	1.0	3.6	0.4	0.2	1.0	11.0	2.8	3.1	0.6	0.0	4.4	22.1	40.3	86.2	38.8	25.8	15.0	28.1	25.0	14.2	22.2	0.0	6.2	3.2	3.8	7.3	34.5	11.3	0.0	26.8	1.2	5.2	25.5	1.1	0.0	0.6	49.9	7.0	0.0	0.0	0.0	1.1	43.4	1.6	17.3	0.5	34.5	0.0	0.0	7.4	62.0	52.5	9.5	29.6	32.1	1.0	0.0	8.0	0.3	0.0	1.8	0.0	30.3	0.0	5.2	1.1	6.1	14.4	1.6	7.5	0.0	4.3
GIT1		ENSG00000108262	"GIT ArfGAP 1"	Q9Y2X7	17	29573469-29594054	"Plasma proteins, Predicted intracellular proteins"		"GTPase activation"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 78.6;Late spermatids: 70.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004059, HPA004186"	Enhanced		Supported	"Focal adhesion sites,Mitochondria,Cytosol"		NA	NA		53000	"Focal adhesion sites, Cytosol"	Mitochondria	"HPA004059: AB_1078966, HPA004186: AB_1078967"	"unprognostic (3.66e-1)"	"unprognostic (4.46e-2)"	"unprognostic (3.24e-2)"	"unprognostic (6.30e-3)"	"unprognostic (1.46e-1)"	"unprognostic (1.08e-1)"	"prognostic unfavorable (2.54e-6)"	"unprognostic (3.00e-3)"	"unprognostic (2.79e-1)"	"unprognostic (5.23e-2)"	"unprognostic (2.12e-2)"	"unprognostic (3.08e-1)"	"unprognostic (8.48e-2)"	"unprognostic (5.56e-2)"	"unprognostic (7.30e-2)"	"unprognostic (2.10e-1)"	"unprognostic (1.69e-1)"	13.0	8.5	34.0	11.1	38.1	8.0	9.4	18.9	43.4	7.8	9.8	15.6	2.2	11.6	10.0	5.3	13.2	14.0	10.2	12.2	41.5	16.4	7.0	3.7	12.0	12.6	19.2	21.8	13.6	14.3	10.2	8.1	13.8	15.0	8.4	6.9	7.8	11.9	10.3	10.0	20.2	10.9	8.7	11.9	11.1	9.5	42.9	19.8	10.8	11.0	4.5	9.7	9.8	7.5	1.8	4.7	3.0	6.0	5.6	4.9	3.6	17.5	29.4	14.5	25.8	11.6	7.3	16.8	8.7	8.6	10.5	9.4	11.9	6.6	13.3	14.0	11.4	18.8	29.1	15.2	22.4	5.4	17.1	18.2	9.6	14.4	10.6	14.1	12.1	7.9	8.9	25.8	12.1	18.9	15.0	19.5	17.8	7.8	11.5	7.5	18.1	38.2	16.3	10.8	17.8	7.0	29.1	19.4	19.9	9.5	9.7	30.5	26.1	12.3	28.6	43.0	10.8	14.0	16.2	24.0	10.0	14.5	22.0	17.5	9.6	13.2	14.5	16.5	10.4	16.8	0.3	3.6	3.0	4.7	6.0	2.2	1.8	4.5	4.9	4.7	1.7	3.7	2.7	1.2	5.6	3.7	4.0	2.9	3.6	34.0	38.1	18.9	43.4	41.5	16.4	19.2	21.8	15.0	19.8	3.0	1.0	13.7	6.2	24.2	14.0	7.6	0.0	8.1	1.2	5.2	9.8	4.4	1.7	7.1	78.6	27.4	16.3	0.0	8.1	6.7	8.8	8.0	1.1	2.1	7.3	11.1	14.3	14.7	7.8	70.1	13.3	9.2	8.5	4.6	14.3	9.7	8.1	10.5	9.9	5.0	9.3	12.9	5.1	10.4	10.9	24.6	3.0	7.7	13.7	6.7
HSH2D	"ALX, FLJ14886, HSH2"	ENSG00000196684	"Hematopoietic SH2 domain containing"	Q96JZ2	19	16134028-16158575	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 47.4;lymphoid tissue: 33.8"	"Cell type enhanced"	"Detected in many"	14	"B-cells: 71.7;T-cells: 40.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in all"		"basophil: 47.4"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"Daudi: 13.2;HL-60: 13.7;HMC-1: 18.9;NB-4: 44.6;RPMI-8226: 20.0;U-266/84: 12.9;U-937: 43.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA036616			Approved	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA			"Plasma membrane"	"Focal adhesion sites, Cytosol"	"HPA036616: AB_10671962"	"unprognostic (1.69e-1)"	"unprognostic (2.97e-2)"	"prognostic unfavorable (9.46e-6)"	"unprognostic (1.06e-1)"	"unprognostic (5.50e-3)"	"unprognostic (5.21e-3)"	"unprognostic (9.35e-2)"	"unprognostic (4.78e-2)"	"unprognostic (4.21e-3)"	"unprognostic (9.96e-2)"	"unprognostic (1.57e-2)"	"unprognostic (2.22e-2)"	"prognostic unfavorable (6.49e-6)"	"unprognostic (9.17e-3)"	"unprognostic (6.18e-2)"	"unprognostic (3.21e-2)"	"prognostic favorable (3.47e-5)"	1.2	1.1	1.2	31.5	1.1	19.2	1.2	1.1	1.1	1.4	8.9	0.0	5.2	5.5	1.1	6.2	2.0	1.5	10.3	1.2	1.1	1.1	1.3	1.5	6.0	16.7	1.0	0.0	1.1	4.8	0.9	3.7	2.3	0.3	2.2	4.0	1.0	8.8	5.2	1.1	1.1	12.1	0.7	1.1	21.8	5.4	1.1	0.0	8.5	1.7	2.4	33.8	4.7	1.1	14.5	6.0	47.4	8.4	19.0	4.3	3.6	4.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.7	7.0	13.2	0.2	0.0	0.2	0.2	0.0	0.1	0.0	0.7	0.0	0.2	0.1	0.8	0.0	13.7	18.9	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	12.4	0.0	2.8	0.0	44.6	0.0	1.7	0.0	0.9	0.0	20.0	0.1	1.8	0.0	0.0	0.0	0.4	0.1	0.0	0.1	5.1	0.0	0.0	0.0	0.0	0.0	1.9	12.9	7.3	0.0	43.8	0.0	47.4	3.7	23.0	4.3	5.0	3.9	14.5	1.9	2.8	6.0	8.6	1.8	2.3	43.7	19.0	8.4	1.8	2.9	3.6	1.2	1.1	1.1	1.1	1.1	1.1	1.0	0.0	0.3	0.0	3.0	9.9	71.7	0.7	0.2	0.0	0.6	2.5	4.0	4.5	5.2	0.0	2.1	0.0	5.3	0.0	0.0	13.5	0.0	4.4	3.1	0.4	4.3	5.8	0.0	1.1	0.0	8.1	1.8	1.5	0.0	0.0	2.5	10.1	2.8	14.1	0.0	6.8	10.5	0.0	0.3	0.0	0.0	0.3	0.0	0.5	0.1	2.9	40.6	7.7	3.2
IL1RL1	"DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1"	ENSG00000115602	"Interleukin 1 receptor like 1"	Q01638	2	102311502-102352037	"Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Hydrolase, Receptor"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"kidney: 49.7;lung: 77.2;placenta: 95.0"	"Cell type enriched"	"Detected in many"	11	"granulocytes: 477.2"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 7.9"	"Group enriched"	"Detected in many"	5	"basal ganglia: 11.4;cerebral cortex: 6.6;hippocampal formation: 5.6;midbrain: 3.8;pons and medulla: 14.6"	"Group enriched"	"Detected in some"	59	"basophil: 17.1;eosinophil: 17.0"	"Lineage enriched"	"Detected in single"	59	"granulocytes: 17.1"	"Group enriched"	"Detected in some"	6	"HHSteC: 55.4;HMC-1: 82.4;HUVEC TERT2: 40.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA007406, HPA007917"	Uncertain		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"	"Secreted to blood"	NA	NA	19100000	1700000	"Plasma membrane"	"Focal adhesion sites, Cytosol"	"HPA007406: AB_1079128, HPA007917: AB_1079129"	"unprognostic (7.25e-2)"	"unprognostic (9.72e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.28e-2)"	"unprognostic (5.28e-2)"	"unprognostic (1.98e-2)"	"unprognostic (3.25e-3)"	"unprognostic (2.07e-1)"	"unprognostic (2.77e-1)"	"unprognostic (4.50e-2)"	"unprognostic (8.58e-2)"	"unprognostic (9.74e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.32e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.60e-3)"	10.7	7.5	1.4	2.0	11.4	0.9	6.9	0.5	6.6	2.6	3.1	0.1	0.1	1.3	1.7	0.9	2.7	0.8	7.8	16.6	5.6	1.8	49.7	6.2	77.2	1.4	3.8	0.0	0.7	2.8	0.8	1.8	95.0	14.6	1.9	2.3	1.0	0.7	5.7	2.8	1.1	2.0	3.3	5.0	1.0	6.7	0.8	0.3	0.0	5.6	0.7	0.9	6.0	2.6	0.0	0.0	17.1	0.0	0.2	0.2	0.0	0.2	0.0	0.1	0.0	3.4	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.3	0.0	1.3	0.1	0.0	0.0	9.7	0.1	0.1	55.4	0.4	82.4	1.1	0.3	1.3	8.9	0.1	40.2	0.0	0.2	0.1	0.1	0.0	0.1	1.8	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	3.3	0.1	0.1	0.7	0.1	0.0	0.0	0.0	0.1	0.1	0.1	17.1	0.0	17.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.4	11.4	0.5	6.6	5.6	1.8	3.8	0.0	14.6	0.3	8.9	22.8	0.0	15.1	7.6	0.0	1.8	0.0	12.0	13.6	1.8	0.0	0.0	0.0	0.0	0.2	29.2	0.0	0.0	0.4	0.1	4.2	8.9	477.2	0.0	0.0	0.0	0.0	44.2	0.3	0.9	0.9	11.2	3.3	0.0	0.0	0.0	21.7	0.0	0.0	0.0	0.2	38.8	5.2	0.0	0.0	4.4	0.0	4.3	0.0	11.1
ILK		ENSG00000166333	"Integrin linked kinase"	Q13418	11	6603708-6610874	"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004041, HPA048437"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA		130000000	"Plasma membrane, Focal adhesion sites"	Nucleoplasm	"CAB004041: AB_2127050, HPA048437: AB_2680391"	"unprognostic (1.78e-1)"	"unprognostic (2.26e-2)"	"unprognostic (5.26e-2)"	"unprognostic (2.12e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.19e-3)"	"unprognostic (5.25e-3)"	"unprognostic (1.49e-2)"	"unprognostic (9.65e-2)"	"unprognostic (2.64e-1)"	"unprognostic (8.12e-2)"	"prognostic favorable (2.44e-4)"	"unprognostic (4.01e-3)"	"unprognostic (9.27e-2)"	"unprognostic (2.42e-1)"	"unprognostic (6.36e-3)"	20.9	17.6	11.0	22.3	11.9	7.5	37.0	9.4	14.6	40.2	75.1	14.7	41.9	13.5	75.4	25.2	35.7	33.2	41.1	35.1	11.1	9.2	21.6	15.1	21.9	18.9	11.5	14.0	24.2	22.3	20.4	10.9	22.2	11.5	39.9	24.6	19.3	19.4	89.9	18.5	12.4	22.2	103.5	10.6	20.2	33.2	14.2	11.0	8.2	17.5	14.1	13.6	60.8	25.9	19.5	45.9	76.5	49.4	45.3	25.8	63.7	23.9	18.5	29.2	10.1	45.2	32.1	13.3	35.3	69.8	41.8	51.0	19.3	28.3	9.0	9.4	57.7	41.0	19.3	16.3	29.9	42.0	15.7	14.8	13.0	17.7	15.0	30.3	10.4	14.9	30.8	14.1	28.2	21.6	42.9	39.8	7.8	11.9	10.7	54.5	18.0	9.2	17.8	18.4	20.4	21.8	9.6	15.3	9.6	30.6	19.2	5.1	11.5	16.7	23.1	19.4	29.8	16.1	11.9	46.0	52.5	23.7	21.7	17.1	7.8	4.8	12.7	38.9	15.7	24.4	48.3	49.4	76.5	25.8	47.9	25.1	19.5	23.3	24.4	45.9	17.1	14.7	18.5	31.7	45.3	44.4	18.5	25.7	63.7	11.0	11.9	9.4	14.6	11.1	9.2	11.5	14.0	11.5	11.0	41.7	17.0	28.3	58.4	44.9	13.9	0.3	66.2	18.7	15.9	54.1	7.9	94.6	49.7	120.2	46.5	56.1	64.4	46.7	108.6	153.9	93.0	39.7	29.0	24.9	111.6	7.9	36.5	84.1	50.9	110.9	66.2	80.3	81.0	196.6	43.0	50.2	101.4	57.5	138.6	74.7	29.6	155.2	137.9	31.1	15.7	37.8	92.0	54.3	41.7	41.9
INPP5E	"CORS1, JBTS1, pharbin, PPI5PIV"	ENSG00000148384	"Inositol polyphosphate-5-phosphatase E"	Q9NRR6	9	136428619-136439823	"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins"	"Lipid metabolism"	Hydrolase	"Ciliopathy, Disease mutation, Joubert syndrome, Mental retardation, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA065758	Approved		Supported	"Nucleoplasm,Golgi apparatus,Focal adhesion sites"		NA	NA			"Golgi apparatus, Focal adhesion sites"	Nucleoplasm	"HPA065758: AB_2685554"	"unprognostic (1.99e-1)"	"unprognostic (8.68e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.23e-2)"	"unprognostic (4.00e-1)"	"unprognostic (6.92e-2)"	"unprognostic (9.60e-3)"	"unprognostic (3.21e-1)"	"unprognostic (5.81e-2)"	"unprognostic (2.65e-2)"	"prognostic favorable (1.82e-4)"	"unprognostic (2.03e-1)"	"unprognostic (3.04e-2)"	"unprognostic (3.76e-1)"	"unprognostic (5.48e-2)"	"unprognostic (4.64e-1)"	"unprognostic (2.66e-2)"	14.3	11.2	14.9	15.3	10.4	8.9	19.2	19.9	19.1	10.5	10.7	11.5	11.1	10.3	13.1	10.1	8.4	17.2	9.4	11.9	12.6	12.0	10.2	9.0	10.1	13.5	8.4	12.3	14.7	11.6	11.4	12.3	9.8	13.2	9.9	5.2	11.0	14.4	12.9	11.6	18.2	10.7	10.7	6.6	19.4	8.6	15.2	10.3	8.5	12.5	6.2	10.7	8.8	19.3	2.6	1.0	1.9	0.5	0.0	2.4	0.6	6.2	7.2	8.5	8.4	4.3	5.6	10.5	7.5	4.4	5.8	3.7	7.4	4.4	7.8	7.7	6.3	8.3	17.5	3.7	5.1	2.2	24.3	14.7	5.2	12.4	4.9	7.3	6.1	8.5	6.0	4.8	6.4	5.7	6.9	5.6	10.0	8.8	7.2	4.9	10.3	7.8	13.4	5.5	3.9	12.0	14.3	6.5	5.8	5.2	6.1	8.9	8.0	7.2	6.8	5.2	6.1	10.9	9.1	8.0	17.9	6.7	7.2	13.0	7.8	6.3	3.3	9.2	5.4	6.5	0.0	0.5	1.9	2.0	0.0	1.3	2.6	2.3	1.5	0.5	1.7	0.8	1.6	0.4	0.0	0.3	1.0	2.4	0.6	14.9	10.4	19.9	19.1	12.6	12.0	8.4	12.3	13.2	10.3	3.0	5.8	2.9	1.5	4.8	7.1	4.1	7.6	6.7	3.4	3.5	2.0	2.0	1.7	4.5	0.3	5.8	2.8	0.0	4.8	2.0	3.9	2.0	9.2	3.0	2.6	14.3	5.8	2.5	3.8	0.7	6.9	3.5	5.0	4.6	2.9	8.5	5.3	0.0	5.3	2.2	11.4	0.0	4.8	9.8	7.8	4.3	0.7	4.3	4.3	1.6
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	"Integrin subunit beta 1"	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Ductal cells: 1163.1;Pancreatic endocrine cells: 917.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-RPE1: 196.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"		NA	NA		540000000	"Plasma membrane, Focal adhesion sites"	"Endoplasmic reticulum"	"CAB003434: AB_303570, HPA059297: AB_2732634, HPA069003: AB_2732125"	"unprognostic (3.07e-2)"	"prognostic unfavorable (5.01e-4)"	"unprognostic (8.67e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.87e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavorable (3.36e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.36e-3)"	"unprognostic (3.68e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.08e-2)"	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17.0	80.2	20.2	84.2	56.2	59.9	45.0	49.8	68.7	15.0	14.4	47.3	85.8	55.4	34.5	23.0	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58.0	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	45.6	67.0	36.2	40.1	87.3	75.2	31.6	153.5	89.0	73.1	66.9	15.0	106.9	12.3	27.8	128.7	48.0	31.9	10.9	87.3	81.6	12.1	8.8	14.8	31.9	17.5	61.5	3.3	14.7	76.2	47.8	76.9	31.3	196.1	89.8	6.1	10.2	5.4	120.5	7.5	5.7	3.3	8.0	13.9	34.0	3.7	26.8	2.2	104.2	13.2	8.6	21.4	47.8	8.1	34.4	61.5	10.9	11.9	100.4	94.2	54.7	66.9	51.1	5.0	1.1	6.9	69.4	14.1	36.9	1.6	9.8	4.3	25.5	17.8	6.0	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15.0	14.4	23.0	11.1	19.5	18.8	318.6	128.6	76.4	295.7	485.6	32.6	175.3	242.0	164.6	252.5	214.6	29.5	156.7	11.6	1163.1	4.3	314.7	83.6	70.0	355.7	460.3	265.1	177.2	86.6	221.3	161.3	36.5	185.6	387.9	152.7	9.7	235.6	174.3	325.6	83.0	81.4	76.8	917.0	113.2	565.7	64.3	45.2	627.3	497.4	10.0	63.7	149.1	183.8	106.6	98.8	257.2
JAK2	JTK10	ENSG00000096968	"Janus kinase 2"	O60674	9	4984390-5128183	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 36.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 40.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 40.8"	"Group enriched"	"Detected in many"	5	"ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013089, HPA040820, HPA043870"	Approved		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		No	No			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708"	"unprognostic (2.24e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (5.50e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.72e-2)"	"unprognostic (3.85e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.37e-3)"	19.8	8.8	11.5	19.0	10.5	19.0	17.7	14.7	14.4	17.8	10.6	7.0	10.3	7.2	14.8	13.6	12.4	13.4	14.6	27.6	10.3	6.7	7.7	5.6	16.1	19.4	7.0	10.5	15.9	6.7	10.1	7.5	12.0	10.0	12.0	7.4	9.4	7.2	7.4	14.4	19.0	12.3	10.4	11.7	21.5	14.1	10.1	9.0	13.6	8.6	6.5	13.5	13.9	15.6	2.1	9.6	40.8	7.5	3.4	2.1	2.5	2.5	1.5	1.5	2.5	19.4	5.0	0.4	3.5	3.0	2.7	1.8	0.1	0.8	0.1	0.8	2.1	2.2	0.9	1.6	2.1	2.0	27.4	0.5	56.1	3.0	0.7	4.0	3.8	2.9	4.1	0.9	1.1	1.8	3.3	2.5	2.0	4.0	6.5	4.8	0.9	0.9	5.4	1.3	1.3	1.7	1.9	2.8	0.8	2.0	1.3	1.7	0.9	1.0	1.5	1.1	1.6	0.8	6.7	5.1	4.1	1.4	4.2	2.4	1.2	2.3	0.5	5.3	1.9	2.0	40.8	7.5	13.4	2.1	7.3	1.7	2.1	1.6	1.2	9.6	1.9	0.9	1.1	7.1	3.4	5.8	3.6	1.6	2.5	11.5	10.5	14.7	14.4	10.3	6.7	7.0	10.5	10.0	9.0	14.9	6.4	6.9	2.8	8.7	7.4	22.0	0.0	5.3	7.9	7.0	7.9	1.8	1.7	3.0	7.4	8.7	3.9	23.3	3.4	0.8	7.0	1.7	13.9	1.6	11.9	7.9	2.9	4.9	36.0	5.3	21.9	27.7	5.0	16.2	4.2	12.2	5.4	14.4	31.5	2.5	11.1	0.0	5.0	14.9	5.7	7.3	2.9	5.0	3.3	4.1
LASP1	"Lasp-1, MLN50"	ENSG00000002834	"LIM and SH3 protein 1"	Q14847	17	38869859-38921770	"Cancer-related genes, Plasma proteins, Predicted intracellular proteins"	"Ion transport, Transport"	Actin-binding	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 124.5"	"Cell type enhanced"	"Detected in many"	8	"Late spermatids: 467.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA012072, CAB022049"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA		26000000	"Plasma membrane, Cytosol"	"Focal adhesion sites"	"CAB022049: , HPA012072: AB_1852714"	"unprognostic (1.23e-1)"	"unprognostic (2.09e-2)"	"unprognostic (1.77e-1)"	"prognostic unfavorable (4.57e-4)"	"unprognostic (1.47e-1)"	"unprognostic (3.03e-2)"	"prognostic unfavorable (2.41e-4)"	"unprognostic (1.06e-3)"	"unprognostic (2.24e-1)"	"unprognostic (9.60e-2)"	"unprognostic (9.87e-3)"	"unprognostic (1.01e-1)"	"unprognostic (9.65e-3)"	"unprognostic (1.29e-3)"	"unprognostic (3.95e-2)"	"unprognostic (1.60e-3)"	"unprognostic (4.53e-2)"	51.2	20.0	23.8	40.3	22.4	45.4	35.5	15.5	25.7	23.6	57.4	16.3	18.7	54.4	23.4	24.1	22.4	20.8	48.3	15.2	18.4	23.3	33.1	47.5	33.3	44.2	20.0	14.3	28.4	30.1	10.1	17.6	40.0	16.1	18.9	38.6	24.2	22.4	24.1	10.7	18.3	124.5	21.3	12.2	43.1	39.5	13.9	12.9	40.5	18.3	18.7	33.7	22.0	28.3	6.4	13.9	34.0	19.9	17.3	16.5	13.1	35.4	73.9	21.6	19.1	31.8	34.5	37.3	44.6	43.6	47.0	34.6	22.0	38.6	16.2	37.3	68.9	26.7	56.5	9.8	33.9	41.2	11.8	5.3	7.7	21.4	38.3	30.2	17.8	23.4	30.6	11.9	39.8	11.3	29.4	31.5	10.0	13.1	5.4	65.4	11.7	21.1	27.5	10.8	31.2	18.5	11.9	11.5	20.4	57.7	31.2	3.2	7.9	26.5	27.9	23.1	41.8	44.0	21.8	55.0	28.2	41.2	33.0	27.0	14.0	18.4	12.6	29.8	16.0	33.9	9.9	14.8	16.8	16.5	17.1	11.3	6.4	8.4	11.0	13.9	6.3	7.2	10.9	34.0	17.3	19.9	10.7	10.7	13.1	23.8	22.4	15.5	25.7	18.4	23.3	20.0	14.3	16.1	12.9	38.7	25.9	38.3	19.5	37.2	55.7	0.8	66.2	32.1	19.4	69.8	9.8	4.3	14.9	58.2	85.5	48.9	225.0	0.0	65.7	33.5	47.6	22.3	51.8	85.9	75.8	25.4	83.1	70.6	116.7	467.6	48.1	58.0	33.7	52.3	91.2	21.1	95.7	106.3	37.4	62.1	22.0	64.7	29.7	2.1	4.1	24.8	5.4	60.9	75.9	23.8
LDB3	"CMD1C, KIAA0613, PDLIM6, ZASP"	ENSG00000122367	"LIM domain binding 3"	O75112	10	86668449-86736068	"Disease related genes, Plasma proteins, Predicted intracellular proteins"			"Cardiomyopathy, Disease mutation, Myofibrillar myopathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	21	"heart muscle: 213.9;skeletal muscle: 329.7;tongue: 110.3"	"Cell type enriched"	"Detected in some"	41	"Cardiomyocytes: 1579.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HSkMC: 5.9;hTERT-RPE1: 5.8;SCLC-21H: 9.6;SK-MEL-30: 4.6"	"Low region specificity"	"Detected in all"							HPA048955	Enhanced		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA		450000	"Focal adhesion sites, Cytosol"	Nucleoplasm	"HPA048955: AB_2680568"	"unprognostic (1.60e-1)"	"unprognostic (9.01e-2)"	"unprognostic (4.87e-2)"	"unprognostic (6.92e-2)"	"unprognostic (5.55e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.61e-2)"	"unprognostic (2.54e-3)"	"unprognostic (3.55e-2)"	"unprognostic (4.72e-4)"	"unprognostic (3.07e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.62e-2)"	"unprognostic (3.16e-1)"	6.4	0.4	0.9	1.3	1.6	0.2	0.5	0.1	1.3	2.8	2.3	0.0	4.9	0.4	4.2	9.9	9.9	1.3	1.0	213.9	1.7	1.0	0.3	0.2	0.4	0.2	2.6	0.0	1.5	0.3	0.3	0.1	0.5	0.0	4.4	0.8	4.7	7.6	3.1	329.7	0.3	1.2	3.6	6.7	0.2	0.7	0.5	0.0	0.0	2.8	110.3	10.2	1.9	0.9	0.9	0.6	1.8	0.4	0.6	0.6	0.0	0.3	0.2	0.4	3.1	0.4	0.1	0.3	0.4	0.3	0.1	0.2	0.3	0.3	0.2	0.6	0.0	0.7	0.4	0.2	0.0	0.1	0.9	0.7	0.7	0.9	0.1	0.1	0.1	1.6	5.9	0.5	0.1	0.0	5.8	0.0	0.7	0.2	1.8	0.3	1.5	0.4	0.2	0.4	0.4	0.3	0.0	2.0	0.1	0.0	1.1	9.6	1.8	0.3	0.2	4.6	1.4	0.3	0.2	0.0	0.3	0.5	0.4	0.1	0.2	0.6	0.4	0.7	0.3	0.5	1.8	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.3	0.2	0.9	0.5	0.6	1.4	0.6	0.4	0.6	0.3	0.0	0.9	1.6	0.1	0.6	1.7	1.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.9	1.7	1579.0	0.0	0.0	0.0	1.8	0.0	0.1	0.0	0.0	18.3	0.7	0.0	0.0	1.0	0.0	0.7	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	13.2	10.3	0.4	1.7	0.0	0.0	1.0	0.1	0.0	6.3	0.0	3.4	38.8	33.0	0.6	1.0	0.0	0.0	0.0	0.0	0.1
LPXN	LDPL	ENSG00000110031	Leupaxin	O60711	11	58526871-58578220	"Predicted intracellular proteins"	"Cell adhesion, Transcription, Transcription regulation"	Activator		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 42.0;lymphoid tissue: 75.1"	"Cell type enhanced"	"Detected in many"	6	"granulocytes: 51.8;Kupffer cells: 53.4;Macrophages: 67.3;T-cells: 74.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 40.0;HMC-1: 67.0;Karpas-707: 57.4;U-2197: 40.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043741, CAB046478, HPA061441"	Enhanced		Supported	"Nuclear speckles,Focal adhesion sites,Cytosol"		No	No			"Focal adhesion sites"	"Nuclear speckles, Cytosol"	"CAB046478: AB_10603113, HPA043741: AB_2678647, HPA061441: AB_2684518"	"unprognostic (1.61e-3)"	"unprognostic (6.91e-2)"	"unprognostic (6.54e-2)"	"prognostic favorable (8.81e-4)"	"unprognostic (5.16e-2)"	"unprognostic (2.07e-3)"	"unprognostic (2.16e-2)"	"unprognostic (8.87e-3)"	"unprognostic (5.18e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.39e-2)"	"unprognostic (3.05e-1)"	"unprognostic (3.60e-3)"	"unprognostic (1.91e-1)"	"unprognostic (5.25e-2)"	"unprognostic (2.55e-1)"	"unprognostic (2.41e-3)"	16.3	5.6	5.1	34.2	4.7	4.2	5.1	3.5	4.9	4.4	6.7	9.0	4.1	5.1	6.5	5.9	3.8	4.7	7.2	3.9	5.2	5.1	6.3	7.1	19.7	37.2	6.3	2.5	6.6	5.6	3.9	4.8	2.6	5.0	5.7	9.6	6.2	7.6	5.1	2.1	3.7	16.0	4.7	11.4	32.2	5.7	5.9	4.9	75.1	6.8	4.4	52.9	11.2	3.9	19.9	36.5	3.8	19.1	20.1	42.0	20.9	0.3	0.4	0.4	0.7	1.5	1.9	0.2	10.0	40.0	2.5	4.5	0.0	1.0	29.2	0.4	12.1	1.8	0.3	0.3	27.2	10.5	12.7	0.1	1.3	0.2	0.1	2.6	7.9	67.0	1.5	0.6	34.5	4.5	2.4	16.1	17.9	0.3	57.4	20.2	0.2	27.6	9.9	0.3	0.4	9.1	0.4	0.5	25.1	1.6	14.0	0.2	0.3	0.4	0.6	3.9	0.6	0.5	2.3	15.7	6.3	1.8	40.3	8.9	3.7	3.5	28.7	14.6	7.1	14.2	1.7	19.1	3.1	28.2	11.0	42.0	19.9	29.0	32.4	36.5	11.5	22.6	26.8	3.8	20.1	5.6	33.1	38.7	20.9	5.1	4.7	3.5	4.9	5.2	5.1	6.3	2.5	5.0	4.9	0.0	7.0	47.0	4.0	8.7	3.4	1.6	0.0	4.0	2.3	0.0	3.9	2.3	3.3	2.2	22.9	8.0	4.7	0.0	4.9	1.1	4.5	3.3	51.8	6.7	46.1	1.6	5.8	2.5	53.4	6.2	1.7	67.3	18.6	36.9	2.9	4.1	2.8	4.9	3.5	4.2	4.7	6.5	4.1	7.4	4.1	8.4	2.1	74.6	5.2	26.4
LRCH4	"LRN, LRRN1"	ENSG00000077454	"Leucine rich repeats and calponin homology domain containing 4"	O75427	7	100574011-100586153	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 153.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 45.7;NB-4: 70.7"					"Low region specificity"	"Detected in all"			"HPA037667, HPA037668"	Enhanced		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA			"Nucleoplasm, Focal adhesion sites, Cytosol"		"HPA037667: AB_10671882, HPA037668: AB_10672910"	"unprognostic (2.41e-1)"	"unprognostic (2.53e-2)"	"prognostic unfavorable (1.61e-7)"	"unprognostic (8.32e-3)"	"unprognostic (2.76e-2)"	"unprognostic (3.96e-3)"	"unprognostic (8.98e-3)"	"unprognostic (3.72e-2)"	"unprognostic (2.52e-1)"	"unprognostic (5.51e-2)"	"unprognostic (2.63e-3)"	"unprognostic (7.81e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.40e-2)"	"unprognostic (7.96e-2)"	"unprognostic (1.26e-2)"	11.4	15.2	14.5	32.0	25.7	52.7	13.8	19.7	22.2	12.0	14.0	16.4	11.8	22.0	12.3	9.6	14.4	14.0	15.9	10.2	16.2	9.1	16.1	12.2	20.8	39.1	25.8	13.1	23.7	17.3	8.9	22.8	26.4	19.2	14.6	7.2	18.3	23.5	13.0	15.8	15.0	27.8	8.1	25.7	54.5	14.9	43.3	23.1	31.1	20.0	6.8	25.2	9.9	12.0	5.9	6.2	24.2	8.4	1.4	7.3	2.9	7.9	4.5	4.5	4.0	2.7	2.1	8.6	7.7	3.5	4.5	3.7	7.5	11.7	5.8	8.7	2.3	4.8	6.9	2.2	3.2	1.3	5.7	6.0	6.6	5.3	3.5	8.6	11.4	45.7	3.5	3.5	3.8	2.1	2.9	4.6	15.2	8.2	11.9	3.2	15.0	13.1	70.7	4.7	7.4	5.3	14.6	3.7	7.1	3.5	2.8	5.9	8.8	3.7	11.8	9.0	6.1	7.9	24.9	7.2	6.2	11.3	8.6	4.6	12.1	5.7	5.2	4.8	28.3	10.6	12.6	8.4	11.9	5.2	6.8	4.7	4.7	5.1	5.9	6.2	5.9	7.3	5.9	24.2	1.4	4.7	5.9	5.2	2.9	14.5	25.7	19.7	22.2	16.2	9.1	25.8	13.1	19.2	23.1	8.9	16.7	24.7	13.8	10.6	13.6	0.7	25.5	6.7	6.8	21.0	39.3	33.4	13.3	27.1	153.1	9.5	22.2	0.0	21.3	11.2	9.5	12.1	18.5	11.3	30.3	12.7	5.8	15.4	53.4	19.7	23.0	33.3	13.5	52.3	12.9	15.5	23.1	14.0	9.6	6.2	29.9	19.4	12.2	42.6	28.7	10.0	86.4	42.9	11.0	14.2
NUP214	"CAIN, CAN, D9S46E, N214"	ENSG00000126883	"Nucleoporin 214"	P35658	9	131125561-131234670	"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters"	"Host-virus interaction, mRNA transport, Protein transport, Translocation, Transport"		"Cancer-related genes, Disease mutation, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 131.5"	"Cell type enhanced"	"Detected in many"	9	"Early spermatids: 225.7;Kupffer cells: 255.0;Late spermatids: 282.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 43.7;neutrophil: 131.5"	"Group enriched"	"Detected in many"	5	"granulocytes: 131.5;monocytes: 43.7"	"Cell line enhanced"	"Detected in all"		"K-562: 73.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048789			Approved	"Nucleoplasm,Vesicles,Focal adhesion sites"		NA	NA		100000	Nucleoplasm	"Vesicles, Focal adhesion sites"	"HPA048789: AB_2680521"	"unprognostic (1.30e-1)"	"unprognostic (9.51e-3)"	"unprognostic (9.92e-3)"	"unprognostic (1.15e-1)"	"unprognostic (7.42e-2)"	"unprognostic (8.31e-2)"	"unprognostic (1.07e-3)"	"unprognostic (2.10e-2)"	"unprognostic (3.35e-1)"	"unprognostic (4.95e-1)"	"unprognostic (6.60e-3)"	"unprognostic (1.08e-1)"	"prognostic favorable (2.39e-5)"	"unprognostic (5.49e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.53e-1)"	16.9	10.3	11.5	13.8	13.9	29.4	12.9	13.0	14.4	10.2	11.4	19.8	10.4	9.0	15.0	13.7	16.1	12.1	10.2	9.7	9.5	8.1	19.0	15.1	11.7	13.3	13.2	8.8	14.2	17.0	16.7	16.9	13.0	11.3	11.1	10.8	15.3	13.0	11.1	15.5	17.5	11.7	11.1	14.3	35.8	12.3	63.7	13.3	27.4	11.8	7.6	16.8	10.7	11.2	1.2	16.8	131.5	43.7	1.2	0.8	17.9	6.8	9.8	8.4	5.0	6.8	6.6	8.8	6.1	6.3	8.0	6.5	8.0	5.0	11.1	4.9	8.4	8.3	15.7	11.3	8.0	7.8	8.0	5.5	6.9	14.0	15.6	6.0	10.8	7.5	7.1	7.4	10.2	8.3	5.1	8.1	7.4	73.0	6.4	8.2	12.8	14.2	16.4	9.1	9.9	8.6	5.0	10.6	11.1	9.2	6.3	7.1	7.4	10.2	9.4	5.3	6.3	12.4	27.0	7.0	14.1	7.9	9.2	9.9	5.6	10.9	10.8	6.9	6.5	8.5	3.5	43.7	17.3	0.7	18.4	0.8	1.2	0.7	0.6	16.8	1.1	0.7	0.7	131.5	1.2	15.0	1.5	0.4	17.9	11.5	13.9	13.0	14.4	9.5	8.1	13.2	8.8	11.3	13.3	17.9	19.9	15.2	9.5	7.7	29.6	24.0	15.3	16.0	15.9	22.7	43.2	10.9	8.3	9.1	225.7	14.6	13.6	0.0	13.1	9.3	11.4	11.4	8.1	11.9	75.5	15.9	19.5	18.4	255.0	282.5	21.6	77.0	10.1	15.4	14.3	14.8	12.0	5.8	19.1	6.7	31.6	6.5	8.1	90.1	44.5	9.5	9.2	11.8	16.3	9.3
PALMD	"C1orf11, FLJ20271, PALML"	ENSG00000099260	Palmdelphin	Q9NP74	1	99645943-99694541	"Predicted intracellular proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 84.9;skeletal muscle: 106.9"	"Cell type enhanced"	"Detected in many"	9	"Cardiomyocytes: 153.8;Ciliated cells: 174.0;Endothelial cells: 169.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HUVEC TERT2: 43.5;LHCN-M2: 14.0;TIME: 60.9;U-87 MG: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017959, HPA030549"	Supported		Supported	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Actin filaments"	"Plasma membrane, Focal adhesion sites"	"HPA017959: AB_1854949, HPA030549: AB_2673518"	"unprognostic (1.48e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.05e-2)"	"prognostic favorable (9.42e-4)"	"unprognostic (7.67e-2)"	"prognostic favorable (5.90e-5)"	"unprognostic (1.54e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.64e-1)"	"unprognostic (8.32e-2)"	"unprognostic (6.18e-2)"	"unprognostic (5.19e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.88e-1)"	"unprognostic (2.70e-1)"	"unprognostic (8.08e-2)"	84.9	18.6	8.3	6.2	4.3	0.0	46.4	1.1	3.7	17.1	6.5	3.9	4.0	1.3	18.6	10.1	16.2	8.7	5.3	59.0	5.6	3.4	5.1	20.9	10.6	3.4	3.9	3.8	17.4	2.2	4.4	4.7	16.8	19.0	8.1	2.6	7.9	34.0	4.4	106.9	18.0	3.5	12.2	4.1	2.3	2.8	7.5	2.2	2.1	3.4	48.2	6.2	6.9	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.6	0.7	0.1	3.0	0.0	0.1	0.0	0.0	0.0	0.0	5.7	7.3	0.0	0.0	0.0	1.1	0.5	0.0	0.0	1.2	43.5	0.0	6.1	0.0	14.0	0.1	0.0	0.0	0.0	0.4	1.9	0.0	10.9	0.0	0.0	2.2	0.2	0.1	0.0	2.8	0.0	0.3	0.6	0.0	60.9	0.0	0.1	4.7	0.0	0.0	0.0	0.0	26.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	4.3	1.1	3.7	5.6	3.4	3.9	3.8	19.0	2.2	6.0	9.3	0.0	9.8	34.2	0.2	153.8	35.7	174.0	45.5	3.5	0.0	0.2	5.0	7.1	73.5	169.5	0.0	0.0	0.2	0.4	4.8	4.7	1.1	55.2	0.5	3.2	1.7	58.9	1.3	7.9	8.6	1.7	23.6	0.0	0.0	54.8	2.5	0.0	22.6	0.0	2.1	0.0	6.1	0.5	0.2	40.7	0.2	0.0	0.0	0.7
PARVA	"FLJ10793, FLJ12254, MXRA2"	ENSG00000197702	"Parvin alpha"		11	12377185-12530801	"Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"				"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"MAIT T-cell: 4.0;memory CD4 T-cell: 1.3"	"Lineage enriched"	"Detected in single"	40	"T-cells: 4.0"	"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 53.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA005964	Approved		Supported	"Actin filaments,Focal adhesion sites,Cytosol"		NA	NA			"Actin filaments, Focal adhesion sites"	Cytosol	"HPA005964: AB_1079569"	"unprognostic (3.87e-2)"	"unprognostic (7.38e-2)"	"unprognostic (3.30e-2)"	"prognostic favorable (1.76e-4)"	"unprognostic (7.37e-3)"	"unprognostic (1.38e-2)"	"unprognostic (6.78e-2)"	"prognostic unfavorable (8.19e-4)"	"unprognostic (1.76e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.82e-2)"	"unprognostic (6.73e-2)"	"unprognostic (6.58e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.82e-2)"	30.5	8.3	7.1	14.4	6.5	0.0	44.0	3.9	8.3	29.2	39.2	3.5	25.8	6.9	40.5	17.6	27.0	17.2	35.2	21.3	6.4	5.3	15.3	10.7	13.2	8.5	5.3	7.8	22.7	16.2	10.1	6.3	16.3	5.5	31.7	16.4	18.3	13.4	35.1	6.4	7.7	13.1	55.9	5.0	8.4	24.2	8.4	2.8	0.4	10.5	8.1	5.0	38.8	33.4	0.0	0.0	0.0	0.0	0.0	4.0	0.1	7.7	7.7	7.2	9.3	36.8	28.6	16.7	29.7	30.7	21.0	19.7	5.7	12.1	0.0	9.9	53.9	2.3	4.8	0.1	15.5	25.1	0.1	3.9	0.0	10.9	4.3	28.3	0.0	0.2	22.5	6.3	8.8	13.8	26.1	26.1	0.0	0.0	0.0	31.2	4.6	0.0	0.0	3.3	4.6	6.7	0.0	17.9	0.0	11.6	7.6	1.1	0.0	22.8	9.2	15.3	16.8	4.3	0.2	32.2	25.4	10.6	13.6	8.1	0.0	0.0	0.0	14.1	0.0	27.9	0.0	0.0	0.0	0.5	0.0	4.0	0.0	1.3	0.4	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	7.1	6.5	3.9	8.3	6.4	5.3	5.3	7.8	5.5	2.8	92.3	24.1	1.7	21.5	12.2	1.5	37.0	20.4	69.6	28.4	26.2	0.0	36.9	33.2	52.3	0.4	35.1	27.4	0.0	58.4	78.2	48.2	29.5	4.7	15.3	5.7	0.0	26.0	40.5	1.6	0.9	38.0	2.5	43.9	1.8	21.5	21.4	55.2	21.0	48.8	29.7	2.1	51.8	48.4	1.1	3.4	7.9	15.9	3.8	29.3	20.3
PDLIM5	"Enh, LIM"	ENSG00000163110	"PDZ and LIM domain 5"	Q96HC4	4	94451857-94668227	"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 129.6;skeletal muscle: 173.0"	"Cell type enriched"	"Detected in all"	8	"Cardiomyocytes: 1784.7"	"Cancer enriched"	"Detected in all"	8	"prostate cancer: 132.0"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	4	"basophil: 51.1"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 51.1"	"Cell line enhanced"	"Detected in all"		"hTERT-RPE1: 51.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013511, HPA016740, HPA020026"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		NA	NA		2200000	"Nucleoplasm, Plasma membrane, Focal adhesion sites"		"CAB013511: AB_2533388, HPA016740: AB_1855153, HPA020026: AB_1855154"	"unprognostic (6.20e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.08e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.33e-1)"	"unprognostic (2.46e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.11e-2)"	"unprognostic (3.15e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.04e-1)"	11.6	4.8	6.2	4.2	6.1	8.7	9.8	3.4	5.8	12.7	11.0	3.7	7.1	5.6	37.5	12.9	14.0	10.2	11.0	129.6	5.3	5.2	12.9	13.9	5.6	5.3	5.4	4.5	10.3	8.1	3.4	6.8	18.9	10.2	15.3	5.4	12.6	15.3	12.5	173.0	5.6	15.8	22.1	4.9	7.0	5.6	5.5	3.7	1.0	5.3	52.9	9.5	17.7	7.1	3.2	5.6	51.1	12.2	2.7	3.9	3.8	8.2	24.4	9.5	3.7	21.0	14.4	3.7	20.1	16.7	11.5	9.3	22.5	18.3	3.3	20.6	20.1	5.9	8.5	12.9	18.8	19.3	5.8	5.4	12.0	15.9	8.5	30.3	3.9	10.8	19.3	16.6	27.6	21.5	51.4	25.9	3.4	5.1	3.6	24.5	8.1	4.0	1.3	3.2	18.1	10.2	1.9	7.0	2.9	12.9	26.4	4.7	6.3	11.0	25.1	5.6	8.0	2.9	1.2	32.4	30.1	4.8	13.0	12.2	2.5	3.2	3.3	16.4	2.8	7.0	51.1	6.8	5.9	3.8	11.8	3.1	3.2	3.7	3.9	5.6	2.5	2.5	3.2	6.8	2.7	12.2	1.9	3.4	3.8	6.2	6.1	3.4	3.9	5.3	5.2	5.4	4.5	10.2	3.7	41.7	23.4	12.7	232.1	172.6	4.3	1784.7	58.6	30.8	37.5	47.1	29.5	9.2	11.6	82.1	14.6	128.1	146.3	23.3	81.9	91.7	90.4	234.4	50.8	159.4	34.4	1.6	105.0	135.1	57.1	6.8	38.3	60.2	59.1	29.7	89.1	79.1	115.5	83.5	62.6	63.8	35.6	77.6	141.3	13.2	30.2	137.1	19.9	15.0	51.0	185.7
PKN1	"DBK, MGC46204, PAK1, PKN, PRK1, PRKCL1"	ENSG00000123143	"Protein kinase N1"	Q16512	19	14433053-14471867	"Enzymes, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003982, CAB010278"	Approved		Approved	"Plasma membrane,Focal adhesion sites,Cytokinetic bridge"		NA	NA			"Plasma membrane"	"Focal adhesion sites, Cytokinetic bridge"	"CAB010278: AB_2163965, HPA003982: AB_1855440"	"unprognostic (3.83e-2)"	"unprognostic (2.14e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.13e-2)"	"unprognostic (1.94e-1)"	"unprognostic (4.58e-1)"	"unprognostic (1.30e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.43e-1)"	"unprognostic (8.55e-3)"	"unprognostic (4.08e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.45e-2)"	"unprognostic (1.70e-1)"	"unprognostic (8.66e-2)"	"unprognostic (4.08e-1)"	"unprognostic (2.24e-2)"	28.8	19.5	19.1	27.6	26.7	39.6	25.3	21.9	19.2	19.2	26.0	20.9	16.5	10.0	25.4	19.7	16.6	22.2	22.5	38.3	17.1	17.6	17.9	16.3	27.9	42.2	19.5	16.3	21.7	32.3	15.8	18.7	22.7	19.2	22.6	6.9	21.5	22.6	22.7	43.2	7.6	16.9	22.5	19.4	39.7	24.2	21.5	18.9	39.2	17.8	13.8	24.0	22.1	30.5	11.5	17.0	24.1	30.6	13.5	20.7	15.2	37.7	22.5	8.4	17.4	13.6	16.1	13.8	13.6	16.3	14.4	13.8	8.8	21.7	36.1	35.2	23.3	18.0	8.8	13.4	6.0	5.6	29.2	17.4	43.2	14.4	18.6	45.1	17.0	27.1	11.5	4.4	8.7	13.7	16.4	33.4	19.2	19.1	25.1	10.6	15.5	25.5	15.7	15.2	13.7	25.8	34.3	11.5	25.9	7.1	6.2	30.6	43.4	8.4	10.8	22.0	4.2	9.7	29.6	49.9	28.6	12.3	34.6	20.6	33.0	30.0	19.7	18.8	34.1	22.4	15.4	17.3	24.1	20.7	24.2	15.7	10.7	14.0	14.2	17.0	11.5	13.1	14.3	21.3	13.5	30.6	11.1	15.9	15.2	19.1	26.7	21.9	17.3	17.1	17.6	19.5	16.3	19.2	18.9	3.0	2.1	24.5	5.5	3.3	36.7	3.5	25.5	1.4	1.2	33.2	15.7	1.9	1.7	23.7	4.1	29.5	2.6	0.0	25.6	12.9	16.0	10.2	2.3	9.6	49.5	46.1	38.6	51.0	56.2	6.7	18.4	27.1	16.9	29.7	12.0	47.4	49.8	9.5	21.5	12.7	25.3	25.8	16.5	6.3	26.6	2.4	3.1	48.4	6.6	3.2
PLEC	"EBS1, PCN, PLEC1, PLTN"	ENSG00000178209	Plectin	Q15149	8	143915147-143976734	"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Cancer-related genes, Disease mutation, Epidermolysis bullosa, Limb-girdle muscular dystrophy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 144.9"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"PC-3: 73.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003847, HPA025967, HPA029906"	Enhanced		Supported	"Intermediate filaments,Focal adhesion sites,Cytosol"		NA	NA		7100000	"Intermediate filaments, Cytosol"	"Focal adhesion sites"	"CAB003847: AB_562198, HPA025967: AB_10601671, HPA029906: AB_10602279"	"unprognostic (1.02e-1)"	"unprognostic (1.37e-3)"	"prognostic unfavorable (4.29e-4)"	"unprognostic (2.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.76e-3)"	"prognostic unfavorable (5.33e-4)"	"unprognostic (1.72e-3)"	"unprognostic (1.13e-2)"	"unprognostic (2.85e-3)"	"unprognostic (5.48e-2)"	"prognostic unfavorable (7.98e-6)"	"unprognostic (2.30e-1)"	"unprognostic (4.04e-2)"	"unprognostic (6.58e-2)"	"unprognostic (5.58e-3)"	20.9	11.0	15.9	16.5	13.3	27.9	13.1	15.0	20.7	20.7	17.7	14.6	16.7	13.1	20.2	16.8	25.1	18.2	29.0	23.4	18.9	10.7	11.2	10.9	16.6	15.0	9.9	13.0	18.0	14.0	8.8	12.0	24.2	13.2	17.5	9.8	13.0	17.8	14.8	144.9	36.4	24.1	24.7	11.0	16.9	21.4	6.7	12.7	16.3	9.2	44.2	24.5	20.2	19.2	1.5	3.4	0.8	4.1	0.7	2.9	3.2	16.5	52.1	3.3	4.1	6.1	13.6	11.9	24.4	10.8	6.5	3.6	7.2	17.4	1.7	19.0	35.8	11.6	19.8	2.2	34.1	2.6	12.4	1.8	6.3	52.9	5.9	9.7	2.0	5.3	15.7	6.7	17.5	34.2	5.8	7.6	1.5	3.0	5.4	7.5	29.2	1.2	3.4	2.2	5.2	73.4	0.3	9.6	4.5	10.9	30.8	3.5	3.5	41.6	8.9	4.0	4.5	10.8	2.4	24.3	25.2	45.7	22.2	28.9	0.8	0.6	1.2	24.1	2.7	35.8	0.0	4.1	0.2	1.4	3.8	2.8	1.4	2.7	2.0	3.4	1.5	2.0	1.1	0.8	0.7	2.7	2.8	2.9	3.2	15.9	13.3	15.0	17.3	18.9	10.7	9.9	13.0	13.2	12.7	26.8	17.0	14.3	46.9	95.9	11.5	31.5	35.7	18.7	31.8	38.4	23.6	26.8	0.0	34.1	0.9	56.3	142.5	0.0	17.6	23.1	42.0	88.8	8.1	52.0	34.6	28.6	30.9	54.0	64.5	2.4	41.1	45.0	32.1	26.2	69.7	11.4	96.9	52.6	70.4	3.3	9.5	6.5	55.6	0.5	5.7	67.0	57.7	11.5	29.8	96.8
PNMA1	MA1	ENSG00000176903	"PNMA family member 1"	Q8ND90	14	73711783-73714372	"Predicted intracellular proteins"		"Tumor antigen"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Spermatocytes: 97.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003817, HPA015007"	Enhanced		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Focal adhesion sites"	"HPA003817: AB_1079646, HPA015007: AB_1855502"	"unprognostic (2.82e-2)"	"unprognostic (3.26e-1)"	"unprognostic (9.50e-2)"	"unprognostic (1.10e-1)"	"unprognostic (2.96e-1)"	"prognostic unfavorable (7.49e-5)"	"prognostic unfavorable (3.00e-5)"	"unprognostic (2.90e-1)"	"unprognostic (5.35e-2)"	"unprognostic (3.63e-1)"	"unprognostic (5.58e-2)"	"unprognostic (4.58e-2)"	"unprognostic (1.67e-3)"	"unprognostic (2.04e-3)"	"unprognostic (4.17e-2)"	"unprognostic (2.23e-3)"	"prognostic unfavorable (4.51e-5)"	19.6	18.0	39.1	11.1	42.4	4.7	17.4	30.4	68.2	16.0	19.3	11.2	15.8	8.2	20.5	32.4	13.9	20.9	14.3	13.1	29.6	33.5	16.4	3.1	8.4	12.5	25.8	39.4	31.8	5.7	6.7	20.9	12.3	27.0	29.0	10.1	8.9	4.6	53.4	5.8	4.5	9.1	29.5	19.8	10.1	10.9	38.1	17.3	6.0	11.0	2.5	7.3	14.8	21.2	3.3	3.6	4.0	4.6	4.8	12.8	6.4	15.0	13.7	23.7	17.6	17.9	19.0	9.8	16.0	9.0	14.7	10.8	12.9	9.4	0.3	11.2	19.4	14.0	10.1	18.2	9.5	15.2	14.3	11.2	8.6	11.5	9.6	19.2	4.7	13.7	16.7	11.5	17.5	11.1	29.0	22.1	9.3	7.4	9.6	19.9	37.0	9.4	11.6	7.1	7.8	48.5	14.9	14.8	0.3	19.3	0.4	28.2	21.6	28.2	6.5	12.6	15.0	31.6	8.1	21.3	29.7	23.9	18.0	12.9	8.5	13.1	4.5	29.3	6.8	9.8	2.6	1.7	4.0	8.4	3.3	5.6	2.9	10.8	8.5	3.6	3.3	10.6	9.7	1.6	4.8	4.6	0.6	12.8	6.4	39.1	42.4	30.4	59.9	29.6	33.5	25.8	39.4	27.0	17.3	6.0	4.0	2.4	6.5	3.4	46.6	16.9	0.0	17.4	3.4	14.0	11.8	6.4	13.3	8.4	68.4	12.6	3.1	0.0	5.9	9.3	17.3	7.4	16.1	0.9	13.5	55.6	18.0	22.1	5.4	42.0	30.2	13.2	18.6	19.8	3.7	60.0	19.1	0.0	79.5	17.9	44.9	71.1	44.2	97.4	36.5	3.3	5.0	13.8	1.7	3.1
PTK2	"FADK, FAK, FAK1, PPP1R71"	ENSG00000169398	"Protein tyrosine kinase 2"	Q05397	8	140657900-141002216	"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins"	Angiogenesis	"Developmental protein, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001842, CAB004036, HPA029671"	Approved		Supported	"Vesicles,Focal adhesion sites,Cytosol"		NA	NA		32000	"Focal adhesion sites"	"Vesicles, Cytosol"	"CAB004036: AB_2269034, HPA001842: AB_1855891, HPA029671: AB_10610288"	"prognostic unfavorable (3.21e-4)"	"unprognostic (3.86e-2)"	"unprognostic (1.95e-1)"	"prognostic unfavorable (9.11e-4)"	"unprognostic (1.93e-1)"	"unprognostic (2.28e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.97e-1)"	"unprognostic (2.96e-2)"	"unprognostic (1.06e-2)"	"unprognostic (2.38e-1)"	"unprognostic (2.80e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.53e-1)"	"unprognostic (2.90e-2)"	22.6	20.4	36.0	14.4	42.3	3.1	19.3	20.5	40.8	24.9	17.9	55.7	23.5	14.5	20.2	29.9	14.6	18.7	18.4	20.0	43.5	23.9	22.3	17.0	21.5	13.0	41.4	31.4	19.4	18.2	33.1	13.0	42.1	30.0	19.2	20.7	11.0	21.9	25.5	17.9	13.5	16.3	21.9	38.0	12.2	17.5	21.2	46.1	2.8	22.5	10.2	14.0	22.2	17.8	8.6	7.2	1.8	3.9	5.2	5.7	4.1	14.5	23.1	32.1	11.5	13.5	14.5	20.7	14.4	20.0	13.4	13.2	10.1	12.0	8.8	32.6	18.3	18.9	17.1	18.8	32.8	20.4	0.1	8.8	19.5	12.8	13.9	18.5	0.0	9.2	9.8	16.2	16.8	23.7	35.4	39.6	12.5	19.6	0.2	17.9	25.2	0.2	0.1	12.4	31.5	25.8	12.9	17.6	0.4	28.4	33.1	12.7	15.9	22.4	7.2	14.5	29.6	17.0	0.3	23.9	13.3	25.0	15.6	16.1	0.0	0.1	0.9	17.2	0.1	17.9	1.8	3.9	0.0	0.3	1.6	0.0	6.8	0.8	0.1	5.3	8.6	5.7	2.0	1.7	5.2	0.9	7.2	0.2	4.1	36.0	42.3	20.5	40.8	43.5	23.9	41.4	31.4	30.0	46.1	29.8	24.9	2.7	51.7	29.7	51.6	26.2	33.1	25.4	20.5	52.4	56.9	27.2	19.9	23.3	34.0	35.8	21.0	0.0	20.0	45.5	28.2	67.2	9.2	14.7	6.8	63.5	24.8	33.7	11.7	33.3	22.2	7.9	23.6	1.0	23.1	41.5	33.4	21.0	20.5	22.6	56.8	97.0	121.7	43.2	62.8	22.6	27.8	1.8	21.0	67.4
PXN		ENSG00000089159	Paxillin	P49023	12	120210439-120265771	"Predicted intracellular proteins"	"Cell adhesion"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Extravillous trophoblasts: 124.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 49.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003841, HPA051309"	Supported		Enhanced	"Focal adhesion sites,Centrosome,Cytosol"		NA	NA			"Focal adhesion sites"	"Centrosome, Cytosol"	"CAB003841: AB_562188, HPA051309: AB_2681436"	"unprognostic (4.00e-2)"	"unprognostic (1.94e-2)"	"unprognostic (3.51e-2)"	"unprognostic (3.55e-3)"	"prognostic unfavorable (1.09e-4)"	"prognostic unfavorable (3.72e-5)"	"prognostic unfavorable (7.12e-5)"	"prognostic unfavorable (1.73e-4)"	"unprognostic (3.12e-2)"	"unprognostic (9.19e-3)"	"unprognostic (2.66e-2)"	"unprognostic (1.73e-1)"	"unprognostic (2.12e-2)"	"unprognostic (3.35e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.75e-2)"	35.4	26.2	17.9	26.7	16.5	31.6	45.9	15.5	18.6	25.0	29.0	12.4	31.7	25.6	27.6	30.9	16.0	29.8	31.8	26.2	18.0	7.6	27.6	13.1	35.8	42.9	15.7	8.1	14.8	16.3	17.6	13.9	34.0	15.8	24.9	23.5	24.7	22.1	40.1	98.5	19.7	34.7	44.4	20.3	34.0	20.6	19.8	14.4	9.9	26.7	22.8	11.6	30.1	45.7	0.5	7.6	49.5	12.3	14.4	26.3	14.5	33.2	16.5	5.9	5.9	11.9	31.0	40.1	28.2	24.6	23.0	12.1	19.2	21.0	2.3	18.5	28.6	22.3	23.8	4.1	51.4	18.4	1.8	3.7	0.4	12.2	6.9	17.2	0.5	0.7	15.1	33.6	24.0	27.4	26.0	40.8	6.2	5.9	3.8	44.9	22.1	2.0	0.7	8.4	14.5	57.5	4.9	9.8	2.0	23.6	32.0	9.7	2.9	25.3	7.8	15.2	14.5	19.2	2.7	53.7	16.0	17.5	19.9	33.5	4.0	2.2	0.8	46.0	5.0	31.2	9.8	12.3	13.4	26.3	4.4	14.2	0.5	12.1	17.2	7.6	0.4	9.6	12.8	49.5	14.4	0.2	1.2	9.1	14.5	17.9	16.5	15.5	18.6	18.0	7.6	15.7	8.1	15.8	14.4	53.6	30.4	3.0	29.8	37.5	7.1	11.5	25.5	28.1	35.2	40.1	31.4	31.3	16.6	30.3	1.2	56.8	59.3	0.0	34.6	124.5	18.0	29.6	17.4	15.3	29.4	11.1	52.5	57.1	49.0	1.6	22.5	13.7	25.3	10.0	49.9	6.9	56.8	50.3	17.7	11.6	30.4	6.5	10.5	3.8	8.0	16.9	20.9	28.7	28.4	33.9
REXO2	"CGI-114, DKFZP566E144, SFN"	ENSG00000076043	"RNA exonuclease 2"	Q9Y3B8	11	114439386-114450279	"Predicted intracellular proteins"		"Exonuclease, Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA038450, HPA038451"	Enhanced		Supported	"Nucleoli,Focal adhesion sites,Mitochondria"		NA	NA		390000	Mitochondria	"Nucleoli, Focal adhesion sites"	"HPA038450: AB_10672516, HPA038451: AB_10697391"	"unprognostic (3.26e-3)"	"unprognostic (2.36e-2)"	"prognostic favorable (6.51e-4)"	"unprognostic (6.84e-3)"	"unprognostic (5.80e-3)"	"unprognostic (1.06e-1)"	"unprognostic (1.40e-3)"	"unprognostic (1.78e-1)"	"unprognostic (8.18e-3)"	"unprognostic (2.49e-2)"	"unprognostic (2.17e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.73e-2)"	"unprognostic (6.75e-2)"	"unprognostic (1.23e-1)"	"unprognostic (7.69e-2)"	"prognostic unfavorable (6.70e-4)"	21.8	31.1	13.5	15.8	14.2	16.2	30.0	14.9	12.6	31.4	36.0	11.2	24.0	8.4	38.4	24.8	33.5	17.7	23.9	64.3	13.3	10.5	35.7	28.6	20.1	13.9	17.0	13.1	28.5	27.7	61.2	24.9	45.0	15.3	32.0	17.7	11.6	61.6	22.8	27.8	22.7	15.8	44.6	15.7	18.6	31.5	29.6	14.5	9.9	20.0	25.2	15.2	34.9	40.6	15.5	28.6	19.0	7.9	18.1	30.5	12.2	27.8	16.2	6.3	16.9	50.7	53.8	15.0	47.3	37.0	23.9	30.5	42.6	47.7	15.3	47.7	41.7	36.3	17.8	14.1	41.8	39.5	14.9	10.9	16.9	22.4	26.5	66.7	12.3	5.4	37.2	40.1	30.2	32.1	42.0	42.7	15.9	31.2	9.4	53.5	6.6	8.9	15.5	19.4	22.3	28.7	7.9	20.6	55.8	34.2	22.7	11.2	7.0	21.7	16.8	19.9	27.5	34.1	6.5	40.4	30.8	36.8	23.7	28.9	7.4	8.8	25.9	21.2	29.1	16.4	19.0	6.0	8.8	14.3	7.9	16.5	15.5	21.6	17.9	7.8	11.7	19.9	16.1	1.5	18.1	7.9	28.6	30.5	12.2	13.5	14.2	14.9	12.6	13.3	10.5	17.0	13.1	15.3	14.5	98.3	49.6	36.3	126.2	123.4	12.0	342.7	43.3	89.7	68.2	90.7	2.0	149.0	235.4	121.0	59.3	101.2	22.2	93.5	62.0	153.2	153.3	156.6	32.2	67.6	83.4	4.8	77.7	89.6	17.6	35.4	195.1	39.5	229.5	53.3	64.2	27.2	110.2	31.6	166.2	264.0	6.7	51.8	115.4	227.9	71.1	142.2	225.1	37.4	70.7	116.6
RTN4R	NOGOR	ENSG00000040608	"Reticulon 4 receptor"	Q9BZR6	22	20241415-20283246	"Disease related genes, Predicted membrane proteins"		Receptor	"Disease mutation, Schizophrenia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 12.0;brain: 33.2"	"Cell type enhanced"	"Detected in many"	6	"Muller glia cells: 9.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 12.0"	"Lineage enriched"	"Detected in many"	9	"T-cells: 12.0"	"Cell line enhanced"	"Detected in many"		"NB-4: 20.5;REH: 28.8;SCLC-21H: 17.6;SK-MEL-30: 13.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB012443			Supported	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA		1300000	"Plasma membrane, Focal adhesion sites"	"Actin filaments"	"CAB012443: "	"unprognostic (1.28e-1)"	"unprognostic (1.28e-2)"	"unprognostic (8.29e-2)"	"unprognostic (6.58e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavorable (7.73e-4)"	"unprognostic (2.19e-1)"	"unprognostic (1.56e-1)"	"unprognostic (3.44e-1)"	"unprognostic (8.90e-3)"	"unprognostic (1.21e-2)"	"unprognostic (9.89e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.30e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.07e-1)"	0.8	1.1	10.9	1.2	7.0	1.3	0.7	33.2	24.6	0.8	1.7	1.2	0.3	3.9	4.9	0.5	0.9	1.3	0.6	1.4	8.8	3.1	0.9	4.0	1.7	1.1	1.4	6.8	1.1	2.7	0.6	1.6	1.1	4.9	1.2	0.6	0.7	1.3	1.2	0.8	5.2	1.8	0.7	2.8	5.9	2.3	1.1	0.5	0.1	1.1	0.4	0.7	0.7	0.7	0.1	1.3	0.0	0.0	0.7	12.0	1.7	4.2	2.0	1.3	3.0	0.0	0.0	0.7	0.4	0.0	0.3	0.1	3.2	1.2	0.2	1.4	0.0	2.1	6.9	0.8	1.8	0.0	0.1	7.4	0.1	1.8	0.4	0.7	0.1	0.2	0.0	2.3	0.0	0.2	0.0	0.0	2.0	0.2	0.2	0.0	5.9	2.2	20.5	4.8	1.2	3.7	28.8	0.0	0.2	0.2	1.8	17.6	2.8	2.0	1.5	13.7	0.3	1.7	0.6	0.0	0.2	8.2	0.0	0.1	0.0	0.5	0.5	0.2	4.2	0.0	0.0	0.0	0.0	5.1	0.0	12.0	0.0	4.5	5.1	0.2	0.1	2.7	5.7	0.0	0.7	0.0	1.3	3.1	1.7	10.9	7.0	33.2	20.1	8.8	3.1	1.4	6.8	4.9	0.5	3.0	0.0	0.0	3.6	4.5	5.3	1.7	0.0	0.0	0.0	0.0	3.9	0.0	0.0	2.4	2.0	1.4	1.3	0.0	3.7	4.3	0.5	3.1	0.0	0.9	1.3	6.4	0.0	0.6	0.0	0.0	0.3	0.0	1.7	1.0	1.4	9.8	2.4	0.0	0.0	0.0	4.8	0.0	0.6	0.0	1.3	4.8	0.0	1.0	1.6	2.6
SCN9A	"ETHA, Nav1.7, NE-NA, NENA, PN1"	ENSG00000169432	"Sodium voltage-gated channel alpha subunit 9"	Q15858	2	166195185-166376001	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Exocrine glandular cells: 27.7;Hofbauer cells: 50.6;Intestinal endocrine cells: 31.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	17	"plasmacytoid DC: 18.6"	"Lineage enriched"	"Detected in single"	24	"dendritic cells: 18.6"	"Cell line enhanced"	"Detected in many"		"BJ: 17.2;BJ hTERT+: 12.8;HHSteC: 14.8;hTERT-RPE1: 12.0"	"Region enriched"	"Detected in some"	5	"hypothalamus: 10.9"	"Low region specificity"	"Detected in all"			"CAB013679, HPA061843"	Uncertain		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB013679: , HPA061843: AB_2684625"	"unprognostic (2.10e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.13e-1)"	"unprognostic (8.98e-5)"	"unprognostic (1.47e-3)"	"unprognostic (9.43e-3)"	"unprognostic (2.28e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.27e-1)"	"prognostic unfavorable (2.30e-5)"	"unprognostic (1.69e-3)"	"unprognostic (6.74e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.46e-1)"	6.6	4.2	3.8	2.8	9.1	4.2	2.7	0.9	4.4	1.8	10.2	0.5	0.1	1.4	0.9	3.8	2.6	1.2	5.8	2.9	2.8	15.9	4.8	8.3	4.5	3.5	4.1	2.3	2.1	4.8	0.6	11.3	9.2	7.3	2.0	7.0	1.7	1.8	1.9	0.9	1.8	4.2	5.2	2.5	12.4	1.7	16.2	0.4	10.3	1.4	1.9	1.2	3.6	1.8	0.0	18.6	0.7	0.1	0.4	0.0	0.0	0.0	1.9	0.1	0.0	7.4	6.5	0.0	17.2	12.8	4.0	1.3	0.5	0.0	0.0	0.0	2.1	0.2	0.0	4.9	0.6	6.6	0.0	1.6	1.3	1.5	1.4	14.8	0.0	0.0	0.4	0.2	6.8	1.3	12.0	0.8	0.9	4.3	5.0	0.6	0.0	2.6	0.0	1.5	0.0	0.5	0.7	2.5	6.5	1.8	7.2	0.8	7.2	0.0	0.0	0.3	3.8	0.2	0.0	0.0	0.0	1.1	0.1	0.3	0.1	0.0	0.0	2.5	0.0	1.4	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.7	0.4	0.1	18.6	0.0	0.0	3.8	9.1	0.9	4.4	2.8	15.9	4.1	2.3	7.3	0.4	11.9	18.4	0.9	0.2	0.9	0.2	1.6	5.1	4.0	7.9	5.2	0.0	0.2	3.3	14.9	1.7	2.2	11.3	0.0	27.7	0.4	1.2	0.2	3.5	6.0	50.6	0.0	31.7	20.3	1.5	1.9	1.1	4.3	3.3	0.0	14.6	1.3	18.8	8.6	0.0	12.2	0.0	0.0	1.0	0.0	0.4	0.4	0.9	0.0	10.7	0.1
SHROOM4	KIAA1202	ENSG00000158352	"Shroom family member 4"	Q9ULL8	X	50591647-50814302	"Disease related genes, Predicted intracellular proteins"		"Actin-binding, Developmental protein"	"Disease mutation, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 27.3"	"Group enriched"	"Detected in many"	5	"Alveolar cells type 1: 23.8;Alveolar cells type 2: 15.2;Endothelial cells: 36.5;Ito cells: 31.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	10	"basophil: 1.6"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 1.6"	"Cell line enhanced"	"Detected in some"		"EFO-21: 6.1;HUVEC TERT2: 23.3;RH-30: 4.5;RPTEC TERT1: 5.0;TIME: 8.7;WM-115: 4.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA010089, HPA010565"	Uncertain		Approved	"Nucleoplasm,Vesicles,Focal adhesion sites"		NA	NA			"Focal adhesion sites"	"Nucleoplasm, Vesicles"	"HPA010089: , HPA010565: AB_1079961"	"unprognostic (2.55e-2)"	"unprognostic (1.43e-1)"	"unprognostic (5.56e-2)"	"prognostic unfavorable (8.37e-4)"	"unprognostic (1.34e-1)"	"unprognostic (1.60e-2)"	"unprognostic (4.30e-3)"	"unprognostic (4.55e-2)"	"unprognostic (2.13e-1)"	"unprognostic (2.93e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.14e-1)"	"prognostic unfavorable (4.66e-4)"	"unprognostic (7.30e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.74e-2)"	"unprognostic (2.75e-1)"	13.1	3.5	5.9	3.6	12.1	2.4	10.1	1.9	7.7	6.4	2.9	27.3	1.6	2.4	6.8	3.6	5.2	4.3	5.7	8.5	8.3	4.8	9.7	1.9	21.4	1.9	15.9	6.5	2.5	1.9	3.6	3.7	15.3	13.0	3.6	3.0	4.8	3.5	3.7	6.0	3.2	2.6	7.4	19.7	2.1	2.4	1.5	15.8	0.0	6.3	6.7	2.1	4.8	4.4	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	1.5	0.1	0.0	6.1	0.8	0.0	0.6	3.7	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.4	0.0	0.0	0.4	0.0	23.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	4.5	0.0	5.0	2.2	0.1	0.0	0.0	0.8	1.3	3.3	0.0	0.1	8.7	0.0	0.0	0.0	0.6	0.4	0.0	0.0	1.2	0.2	4.5	1.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.9	12.1	1.9	7.7	8.3	4.8	15.9	6.5	13.0	15.8	23.8	15.2	0.0	1.7	3.2	0.1	2.5	0.0	2.7	2.3	5.2	0.0	0.4	3.3	0.6	0.0	36.5	0.3	0.0	0.2	2.3	1.9	0.8	3.5	1.0	0.5	0.0	2.9	31.3	3.8	0.0	1.1	1.5	0.0	0.0	2.3	2.8	1.3	0.0	1.1	2.6	0.3	0.0	1.4	0.0	0.9	2.8	0.2	0.0	2.6	1.4
SLC4A7	"NBC3, SBC2, SLC4A6"	ENSG00000033867	"Solute carrier family 4 member 7"	Q9Y6M7	3	27372721-27484420	"Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 48.5"	"Group enriched"	"Detected in many"	10	"Cone photoreceptor cells: 691.1;Rod photoreceptor cells: 667.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-HME1: 38.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB022494, HPA035857"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA			"Plasma membrane"	"Focal adhesion sites, Cytosol"	"CAB022494: , HPA035857: AB_10795135"	"unprognostic (2.94e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.80e-3)"	"unprognostic (1.91e-1)"	"unprognostic (8.48e-3)"	"unprognostic (2.68e-1)"	"unprognostic (6.79e-4)"	"unprognostic (4.13e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.83e-1)"	"unprognostic (8.58e-3)"	"prognostic unfavorable (7.91e-6)"	"unprognostic (1.09e-2)"	"unprognostic (6.68e-2)"	"unprognostic (1.93e-1)"	"unprognostic (7.26e-2)"	14.5	5.0	3.2	10.5	4.6	3.3	17.0	4.0	4.8	10.8	38.2	5.0	8.8	48.5	8.1	12.6	8.4	6.5	12.5	9.3	5.0	3.8	15.3	3.7	9.3	10.3	4.8	1.9	9.0	3.3	2.4	4.4	5.6	4.5	10.3	6.9	20.0	8.3	8.4	5.6	5.6	43.4	18.2	5.8	9.7	7.8	6.1	5.5	6.8	6.3	14.7	15.5	15.0	14.9	1.8	2.0	0.1	0.9	2.4	3.9	0.7	5.9	11.1	10.0	4.6	4.7	8.4	7.1	20.2	9.4	7.8	6.1	3.0	3.1	13.5	1.7	7.8	7.5	2.6	9.5	9.8	12.4	11.4	3.1	6.2	7.6	3.2	8.1	14.0	5.4	6.7	4.3	11.8	38.2	16.5	12.8	8.9	4.1	4.8	16.0	2.1	13.9	3.2	6.6	0.7	11.0	9.5	7.9	2.7	18.3	4.2	2.5	6.3	9.2	6.8	3.1	8.9	15.5	5.4	8.9	18.4	5.1	12.7	15.6	1.8	1.9	7.7	16.1	9.9	8.4	0.0	0.5	0.0	3.0	0.6	2.0	1.2	3.8	3.9	1.4	1.8	1.5	2.7	0.1	2.4	0.9	2.0	3.2	0.7	3.2	4.6	4.0	4.8	5.0	3.8	4.8	1.9	4.5	5.5	0.0	12.8	13.2	28.2	26.1	65.7	18.7	15.3	5.3	25.0	59.3	691.1	4.5	8.3	13.6	6.7	25.3	5.8	0.0	6.2	23.0	30.2	41.3	23.1	5.9	16.9	6.4	36.7	14.7	33.1	5.9	8.3	36.7	33.7	20.8	50.6	45.2	13.6	12.7	9.2	10.5	667.4	38.8	32.8	32.4	21.7	26.8	6.8	33.0	12.2	33.6
SORBS1	"CAP, FLJ12406, KIAA1296, ponsin, SH3D5, sh3p12"	ENSG00000095637	"Sorbin and SH3 domain containing 1"	Q9BX66	10	95311771-95561414	"Predicted intracellular proteins"	Transport			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"smooth muscle: 126.5"	"Cell type enriched"	"Detected in many"	7	"Cardiomyocytes: 479.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"basophil: 7.6;eosinophil: 2.2"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 7.6"	"Cell line enhanced"	"Detected in many"		"CACO-2: 15.2;HMC-1: 26.6;SK-MEL-30: 22.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA027559, CAB032850, HPA043084"	Enhanced		Supported	"Plasma membrane,Focal adhesion sites,Centrosome"		NA	NA			"Focal adhesion sites"	"Plasma membrane, Centrosome"	"CAB032850: AB_2286335, HPA027559: AB_10600812, HPA043084: AB_2678307"	"prognostic favorable (2.84e-4)"	"unprognostic (3.53e-1)"	"unprognostic (1.89e-1)"	"unprognostic (7.85e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.98e-2)"	"unprognostic (5.30e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.65e-2)"	"unprognostic (3.17e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.40e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.80e-1)"	"unprognostic (2.55e-2)"	"unprognostic (5.01e-3)"	95.0	6.4	23.0	16.4	21.6	1.8	23.5	16.8	22.5	14.9	70.2	18.7	22.1	8.1	41.8	12.5	45.0	25.1	28.9	83.7	20.9	8.3	5.9	14.7	8.7	1.4	13.4	14.1	9.8	7.3	17.5	3.5	9.9	19.2	42.0	20.0	6.4	7.2	65.7	46.4	6.3	15.5	126.5	20.6	2.9	40.0	5.5	19.3	0.0	4.0	12.7	1.2	63.9	31.4	0.1	0.0	7.6	1.2	0.6	1.0	0.2	0.7	0.7	6.4	1.6	2.4	0.1	0.9	0.2	0.1	0.2	0.0	15.2	5.7	0.0	1.2	0.1	2.4	0.3	1.2	0.3	0.1	1.8	2.3	3.7	0.2	9.1	0.8	0.0	26.6	0.4	0.2	0.3	0.1	0.1	2.6	0.9	6.0	1.2	0.6	0.4	0.0	0.3	3.0	2.8	1.4	0.5	2.2	0.2	7.2	10.0	2.8	2.0	0.9	0.3	22.8	4.6	1.2	0.2	0.2	0.0	2.3	0.1	1.2	0.8	0.2	0.1	2.8	0.2	6.4	7.6	0.2	2.2	0.7	1.2	1.0	0.1	0.3	0.4	0.0	0.1	0.3	0.1	0.2	0.6	0.2	0.0	0.5	0.2	23.0	21.6	16.8	20.7	20.9	8.3	13.4	14.1	19.2	19.3	20.8	18.1	0.5	5.1	10.3	5.9	479.0	12.7	0.0	2.3	1.8	2.0	17.9	3.3	4.4	61.7	19.0	1.0	0.0	2.6	1.9	15.3	5.3	15.1	42.9	2.7	6.4	5.8	38.6	4.9	26.4	6.9	1.1	13.5	1.0	14.0	18.2	2.8	3.5	72.2	4.3	5.4	0.0	64.3	2.8	4.7	10.9	24.7	0.0	5.2	3.3
TADA1	"ADA1, hADA1, HFI1, STAF42, TADA1L"	ENSG00000152382	"Transcriptional adaptor 1"	Q96BN2	1	166856510-166876327	"Predicted intracellular proteins"	"Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028651	Approved		Supported	"Nucleoplasm,Focal adhesion sites,Cytosol"		No	No			Nucleoplasm	"Focal adhesion sites, Cytosol"	"HPA028651: AB_10602476"	"unprognostic (9.53e-3)"	"unprognostic (2.31e-1)"	"unprognostic (1.05e-2)"	"unprognostic (4.10e-2)"	"unprognostic (1.55e-1)"	"unprognostic (7.09e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.31e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.98e-2)"	"unprognostic (3.64e-2)"	"unprognostic (2.73e-2)"	"unprognostic (6.35e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.26e-2)"	6.5	10.6	13.8	7.1	18.5	17.8	10.2	18.2	20.0	11.3	9.1	17.0	3.4	8.3	10.5	8.6	10.1	9.8	6.6	9.2	13.2	14.6	12.9	28.9	6.7	10.1	11.1	14.3	12.7	7.5	11.3	13.7	12.5	15.0	9.2	10.2	13.4	8.7	8.4	10.7	8.5	9.0	8.5	10.8	7.3	8.0	12.0	10.3	16.7	11.5	7.1	10.9	8.6	7.8	13.4	13.0	8.1	8.2	16.2	19.5	15.1	8.2	7.9	14.9	8.8	4.5	5.8	8.9	4.3	5.3	7.3	6.3	7.2	6.7	15.7	8.5	5.1	5.9	6.3	12.0	7.7	5.9	9.9	11.5	5.2	6.8	11.8	6.7	14.6	9.6	4.4	8.9	4.3	11.0	5.2	5.9	11.9	18.5	9.6	5.6	5.7	18.0	11.6	22.7	13.3	8.9	15.2	6.6	19.9	9.7	11.1	9.6	16.8	7.8	10.1	9.1	14.3	13.8	15.4	4.4	6.0	6.9	6.5	9.1	13.6	18.5	29.4	4.1	6.7	5.6	1.8	8.1	8.1	14.0	8.2	15.5	13.1	15.2	15.8	13.0	13.4	19.5	15.3	1.3	16.2	6.2	8.5	14.3	15.1	13.8	18.5	18.2	20.0	13.2	14.6	11.1	14.3	15.0	10.3	8.9	2.4	2.9	4.3	5.5	7.4	9.4	0.0	4.0	4.5	3.5	7.9	5.3	5.0	3.2	3.4	3.7	3.8	0.0	3.5	6.3	4.0	4.4	4.7	17.1	3.7	1.6	6.9	3.7	5.1	1.3	4.0	2.5	1.7	5.4	5.3	6.6	3.0	0.0	2.8	5.0	5.7	0.0	3.8	4.7	12.9	4.4	6.1	5.3	5.1	3.2
TAS2R42	"hT2R55, T2R24, T2R55, TAS2R55"	ENSG00000186136	"Taste 2 receptor member 42"	Q7RTR8	12	11185993-11186937	"G-protein coupled receptors, Predicted membrane proteins"	"Sensory transduction, Taste"	"G-protein coupled receptor, Receptor, Transducer"		"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in single"		"brain: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			HPA036149	Uncertain		Approved	"Nucleoplasm,Actin filaments,Focal adhesion sites"		NA	NA			"Nucleoplasm, Actin filaments"	"Focal adhesion sites"	"HPA036149: AB_10672080"														"unprognostic (2.45e-2)"	"unprognostic (4.17e-2)"			0.0	0.7	0.2	0.2	0.4	0.0	0.0	1.0	0.2	0.0	0.1			0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.1	0.6	0.0		0.7	0.0	0.0	0.4	0.0		0.1	0.0		0.1	0.0	0.0	0.3	0.1	0.0	0.0	0.4	0.2	0.4			0.1		0.0	0.0	0.0	0.7	0.4	0.0	0.5	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.5	0.0	0.0	0.1	0.0	0.5	0.0	0.4	0.7	0.1	0.6	0.4	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TATDN3		ENSG00000203705	"TatD DNase domain containing 3"	Q17R31	1	212791828-212816626	"Predicted intracellular proteins"		"Hydrolase, Nuclease"		"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA032092	Approved		Approved	"Nucleoplasm,Golgi apparatus,Focal adhesion sites"		NA	NA			Nucleoplasm	"Golgi apparatus, Focal adhesion sites"	"HPA032092: AB_10671086"	"unprognostic (9.81e-2)"	"unprognostic (1.57e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.17e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.74e-1)"	"unprognostic (9.38e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.80e-1)"	"unprognostic (3.88e-2)"	"unprognostic (3.34e-3)"	"unprognostic (5.02e-3)"	"prognostic favorable (1.59e-4)"	"unprognostic (1.93e-1)"	"unprognostic (2.44e-1)"	"unprognostic (3.13e-3)"	"unprognostic (2.96e-3)"	13.0	14.8	14.4	10.9	24.7	11.9	11.0	12.5	22.9	7.6	8.8	16.6	6.8	7.0	8.5	15.2	8.3	8.7	8.3	20.7	13.7	15.2	18.3	11.1	8.5	16.2	14.5	18.9	10.1	11.3	12.8	11.9	8.0	22.1	8.0	8.6	11.4	9.4	8.2	29.4	7.4	8.1	11.6	15.5	11.5	11.9	10.5	12.0	11.3	13.1	8.3	10.8	10.6	6.5	15.6	30.1	23.8	24.1	5.3	6.9	8.7	6.6	6.6	5.8	8.6	9.4	14.1	13.4	7.4	8.0	5.9	7.4	1.7	9.4	14.7	7.0	6.3	3.4	4.3	7.1	10.0	6.4	9.0	9.2	7.4	5.5	3.2	10.9	17.7	9.3	11.3	7.2	8.0	19.9	6.4	8.5	21.0	14.4	12.3	6.5	3.1	15.1	5.9	7.8	8.2	4.3	8.7	11.0	26.3	6.1	3.3	12.4	10.6	8.1	13.8	16.2	11.0	14.7	11.0	5.8	4.5	6.0	9.3	7.2	11.0	16.9	24.4	11.6	14.1	6.7	8.5	15.6	23.8	5.5	23.7	4.9	15.6	6.9	6.6	18.4	12.7	5.5	6.6	17.5	5.3	24.1	30.1	6.4	8.7	14.4	24.7	12.5	22.9	13.7	15.2	14.5	18.9	22.1	12.0	6.0	15.2	14.3	8.7	3.9	14.8	33.0	10.2	10.7	3.4	3.5	17.7	10.9	34.9	14.4	7.5	6.3	3.9	0.0	14.5	14.4	6.0	4.5	6.9	5.5	16.4	14.3	9.8	4.3	25.0	2.9	4.9	17.6	13.5	30.7	4.0	14.9	11.0	7.0	4.6	20.7	27.3	6.5	6.9	21.3	16.9	3.9	7.8	10.2	5.8	5.5
TMEM260	"C14orf101, FLJ20392"	ENSG00000070269	"Transmembrane protein 260"	Q9NX78	14	56488354-56650606	"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins"			"Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"cervix, uterine: 61.0"	"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 69.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003502	Uncertain		Approved	"Nucleoplasm,Focal adhesion sites,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Focal adhesion sites"	"HPA003502: AB_1078314"	"unprognostic (4.63e-2)"	"unprognostic (2.41e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.73e-2)"	"unprognostic (2.51e-1)"	"unprognostic (3.58e-2)"	"unprognostic (2.04e-1)"	"prognostic favorable (7.11e-4)"	"unprognostic (7.14e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.95e-3)"	"unprognostic (3.22e-1)"	"unprognostic (2.23e-3)"	"unprognostic (5.81e-2)"	"unprognostic (8.11e-2)"	"unprognostic (1.32e-1)"	"unprognostic (3.84e-2)"	7.8	7.4	7.3	11.0	10.6	3.8	9.1	13.3	9.9	61.0	8.8	13.7	11.6	8.1	11.8	12.1	6.7	11.4	10.3	6.0	8.9	8.6	10.7	8.7	8.4	8.8	10.8	7.5	14.8	13.6	12.4	17.2	8.7	9.7	8.7	9.1	8.7	7.4	13.0	5.2	8.6	10.7	8.9	12.2	9.2	8.4	10.1	8.3	17.6	12.6	4.6	8.8	10.1	9.7	2.0	4.6	2.9	2.8	6.3	3.5	2.0	7.4	5.2	4.0	8.6	14.4	11.9	7.9	7.9	8.8	5.2	6.3	2.4	5.5	6.0	7.8	5.9	5.9	8.6	9.3	5.8	8.3	7.5	4.7	3.9	2.4	3.3	10.1	5.4	9.4	14.5	10.4	2.9	10.1	9.6	6.8	4.7	4.8	6.5	6.8	4.9	2.8	2.0	3.7	12.2	8.3	4.0	6.4	2.0	8.8	11.0	8.5	4.2	8.9	6.5	5.2	7.9	8.2	8.4	9.5	10.6	4.1	7.9	3.9	3.9	3.1	3.5	6.7	4.0	5.2	0.0	2.8	2.9	3.5	1.9	2.4	1.8	2.4	1.8	2.2	2.0	3.2	2.3	1.4	6.3	1.7	4.6	2.9	2.0	7.3	10.6	13.3	9.9	8.9	8.6	10.8	7.5	9.7	8.3	17.9	12.1	4.2	7.4	4.7	14.2	2.9	0.0	17.4	5.7	21.0	3.9	7.9	1.7	6.8	69.7	4.7	6.3	0.0	3.3	6.5	6.7	8.2	11.5	7.5	5.5	6.4	17.2	8.6	13.9	25.8	14.1	7.8	1.7	5.4	10.8	5.6	5.0	7.0	10.3	3.7	17.1	0.0	4.2	7.9	8.5	4.8	9.3	5.7	10.8	6.8
TMEM35A	"FLJ14084, TMEM35"	ENSG00000126950	"Transmembrane protein 35A"	Q53FP2	X	101078720-101096364	"Predicted membrane proteins"				"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 33.8;seminal vesicle: 46.4"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in many"		"glioma: 6.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 6.5;HUVEC TERT2: 32.3;SH-SY5Y: 8.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048583	Enhanced	Supported	Supported	"Vesicles,Focal adhesion sites,Cytosol"		NA	NA			Vesicles	"Focal adhesion sites, Cytosol"	"HPA048583: AB_2680451"	"unprognostic (7.98e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.35e-2)"	"unprognostic (3.02e-2)"	"unprognostic (3.89e-3)"	"unprognostic (2.77e-2)"	"unprognostic (6.66e-3)"	"unprognostic (1.05e-1)"	"unprognostic (3.34e-3)"	"unprognostic (9.20e-2)"	"unprognostic (4.72e-2)"	"unprognostic (3.49e-4)"	"unprognostic (5.91e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.48e-2)"	"unprognostic (9.37e-3)"	3.6	6.7	12.8	1.7	28.2	0.7	1.3	21.2	28.6	3.3	17.3	2.5	6.8	3.5	7.4	3.9	10.4	4.3	3.6	1.1	14.4	33.8	1.1	0.7	2.6	0.8	12.2	10.0	7.7	0.9	6.1	1.5	0.8	30.0	20.5	9.1	2.9	1.0	46.4	1.3	0.9	4.1	11.8	3.9	1.3	3.4	1.8	2.3	0.0	1.3	0.0	0.9	13.3	2.7	0.2	0.0	0.2	0.1	0.6	0.8	0.4	0.0	0.0	3.4	0.0	2.5	6.5	0.0	0.6	0.4	0.3	0.1	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.1	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	2.2	0.0	1.1	0.0	4.7	32.3	0.0	0.0	0.0	4.1	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.4	8.3	0.0	0.0	0.0	0.8	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.5	0.2	0.5	0.2	0.0	0.0	0.6	0.4	0.2	0.6	0.1	0.0	0.8	0.4	12.8	28.2	21.2	28.6	14.4	33.8	12.2	10.0	30.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	"TNF superfamily member 13b"	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 76.5;lymphoid tissue: 39.6"	"Cell type enhanced"	"Detected in many"	23	"Hofbauer cells: 88.9;Kupffer cells: 144.9;Macrophages: 141.3;monocytes: 457.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 76.5"	"Group enriched"	"Detected in many"	10	"dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7"	"Cell line enriched"	"Detected in some"	7	"U-937: 61.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB009188, HPA030526"	Enhanced		Supported	"Vesicles,Plasma membrane,Focal adhesion sites"	"Secreted to blood"	NA	NA	393000	530000	"Plasma membrane"	"Vesicles, Focal adhesion sites"	"CAB009188: , HPA030526: "	"unprognostic (6.48e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (2.53e-11)"	"unprognostic (1.23e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.25e-1)"	7.2	8.2	3.0	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1.0	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5.0	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1.0	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1.0	31.0	76.5	53.7	0.6	5.3	20.8	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.1	0.3	0.2	0.8	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.0	0.3	0.1	0.0	0.1	3.6	0.1	0.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	1.9	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	8.1	0.0	0.1	0.0	0.0	0.1	3.8	0.1	0.0	3.9	61.0	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31.0	1.0	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3.0	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9	14.9	17.5	3.7	0.7	6.4	0.3	0.5	12.7	2.7	5.7	5.2	0.0	0.5	1.7	2.0	1.0	1.3	0.5	0.0	29.2	0.9	13.3	1.6	4.7	1.5	88.9	0.0	1.2	4.9	144.9	0.2	4.9	141.3	8.5	457.1	0.2	0.4	1.9	0.0	1.8	1.0	0.0	6.5	5.0	0.1	0.1	4.1	0.9	6.2	1.2	1.3
TNNT2	"CMD1D, CMH2, CMPD2"	ENSG00000118194	"Troponin T2, cardiac type"	P45379	1	201359008-201377762	"Candidate cardiovascular disease genes, Disease related genes, Predicted intracellular proteins"		"Muscle protein"	"Cardiomyopathy, Disease mutation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	241	"heart muscle: 679.2"	"Cell type enriched"	"Detected in many"	289	"Cardiomyocytes: 11884.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	18	"RH-30: 189.8"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB015371, HPA015774, HPA017888"	Enhanced		Uncertain	"Nucleoplasm,Nucleoli,Focal adhesion sites"		No	No		50000	"Nucleoplasm, Nucleoli"	"Focal adhesion sites"	"CAB015371: AB_630390, HPA015774: AB_1858354, HPA017888: AB_1858355"	"unprognostic (1.45e-1)"	"unprognostic (2.74e-1)"	"unprognostic (2.33e-4)"	"unprognostic (1.85e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.42e-1)"	"unprognostic (2.91e-2)"	"unprognostic (1.38e-1)"	"unprognostic (8.63e-2)"	"unprognostic (5.50e-3)"	"unprognostic (2.94e-1)"	"unprognostic (1.61e-1)"	"unprognostic (4.76e-2)"	"unprognostic (9.98e-2)"	0.1	0.3	0.1	0.1	0.7	0.0	0.8	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.3	0.0	1.2	679.2	0.9	0.0	1.9	0.0	0.7	0.3	0.1	1.1	0.1	0.3	0.0	0.2	0.7	0.1	0.7	0.0	0.0	0.2	0.1	2.0	1.3	0.0	2.8	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	2.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.1	0.0	0.0	0.4	0.5	0.0	0.0	189.8	0.0	0.0	0.0	0.2	0.1	0.0	0.2	0.0	10.5	0.0	0.0	0.0	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	0.0	2.1	0.9	0.0	0.1	1.1	0.1	0.0	3.0	4.0	0.0	1.1	3.1	1.0	11884.8	0.0	0.0	1.2	1.8	0.0	2.3	0.0	0.5	9.4	0.0	1.6	0.0	0.3	0.9	41.1	0.5	0.0	0.0	2.7	0.0	0.0	0.0	0.0	13.6	0.6	0.0	0.0	4.6	0.5	0.0	0.7	0.8	1.1	0.8	0.5	0.0	0.4	0.0	0.2	6.4	3.5	0.0	2.8	1.4
TRIM71	"LIN-41, LIN41"	ENSG00000206557	"Tripartite motif containing 71"	Q2Q1W2	3	32818018-32897826	"Enzymes, Predicted intracellular proteins"	"RNA-mediated gene silencing, Ubl conjugation pathway"	"Developmental protein, RNA-binding, Transferase"	"Disease mutation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lung: 6.5;testis: 11.1"	"Cell type enhanced"	"Detected in some"	12	"Alveolar cells type 1: 8.9;Extravillous trophoblasts: 13.2;Spermatogonia: 12.6"	"Cancer enriched"	"Detected in some"	28	"testis cancer: 28.6"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 11.9;BEWO: 36.1;Hep G2: 23.3;NTERA-2: 31.9;SuSa: 30.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA038141, HPA038142"	Uncertain		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Plasma membrane, Actin filaments, Focal adhesion sites"		"HPA038141: AB_2675857, HPA038142: AB_10697240"	"unprognostic (2.93e-2)"	"unprognostic (4.29e-3)"	"unprognostic (1.70e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.58e-2)"	"unprognostic (3.27e-2)"	"unprognostic (2.09e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.16e-2)"	"unprognostic (3.04e-1)"	"unprognostic (1.11e-2)"	"unprognostic (3.11e-1)"	"unprognostic (4.36e-6)"	"unprognostic (3.92e-2)"	"unprognostic (9.27e-2)"	"unprognostic (8.17e-2)"	"unprognostic (4.65e-2)"	0.1	0.0	0.7	0.1	1.9	0.5	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	2.7	0.7	2.2	0.0	6.5	0.0	0.2	0.0	0.1	0.0	0.0	0.5	1.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.1	0.1	11.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.5	0.3	0.0	0.1	0.0	0.0	0.0	11.9	0.0	0.0	0.0	36.1	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.6	0.0	23.3	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.0	0.0	0.2	2.5	31.9	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	30.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.1	0.0	0.2	0.3	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.3	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.7	1.9	0.0	0.5	2.7	0.7	0.2	0.0	1.9	0.0	8.9	2.6	0.0	0.0	0.0	0.4	2.8	0.0	1.4	3.4	0.0	0.0	3.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	13.2	0.3	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.9	0.4	0.0	0.0	0.3	12.6	0.0	3.3	0.0	0.0	0.0
TRIP6	"MGC10556, MGC10558, MGC29959, MGC3837, MGC4423, OIP1, ZRP-1"	ENSG00000087077	"Thyroid hormone receptor interactor 6"	Q15654	7	100867138-100873454	"Predicted intracellular proteins"	"Cell adhesion, Transcription, Transcription regulation"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 7.7"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB046454, CAB046460, HPA052813"	Approved		Supported	"Plasma membrane,Focal adhesion sites,Cytosol"		NA	NA		12000	"Plasma membrane, Focal adhesion sites, Cytosol"		"CAB046454: AB_10604048, CAB046460: AB_2303907, HPA052813: AB_2681961"	"unprognostic (7.94e-3)"	"unprognostic (1.06e-1)"	"unprognostic (3.22e-3)"	"unprognostic (2.84e-3)"	"unprognostic (3.52e-2)"	"unprognostic (2.92e-2)"	"unprognostic (3.18e-2)"	"unprognostic (4.61e-3)"	"unprognostic (8.48e-2)"	"unprognostic (4.18e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.25e-2)"	"unprognostic (5.07e-2)"	"unprognostic (9.71e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.25e-1)"	15.5	14.7	10.9	16.2	11.2	6.0	18.1	4.2	7.3	36.7	14.6	9.4	22.5	4.4	28.2	30.8	27.2	18.5	43.5	14.5	8.7	7.7	21.6	24.1	18.4	5.8	11.7	9.4	22.0	19.2	28.0	6.5	13.6	9.7	22.1	3.9	22.7	23.0	38.2	8.3	23.9	6.5	25.5	9.7	7.9	9.9	17.5	7.8	7.3	26.6	30.6	12.6	25.0	23.6	3.1	7.7	0.2	4.7	0.0	1.7	0.5	27.0	11.2	5.8	27.7	8.8	10.2	29.1	16.9	18.1	23.2	21.8	10.5	31.2	1.1	17.8	19.0	28.9	20.2	8.5	32.5	5.9	3.9	11.5	0.1	18.6	0.1	23.2	13.0	1.6	18.5	21.4	15.4	24.2	13.7	11.9	4.1	17.0	0.2	20.0	47.5	0.2	20.5	20.0	11.1	10.0	10.2	5.8	2.7	14.3	6.7	2.1	0.3	14.1	42.7	16.8	9.0	4.5	16.6	18.2	34.1	32.1	36.9	39.4	0.2	0.4	0.1	21.2	1.6	51.3	0.0	1.9	0.2	0.2	3.0	0.6	3.1	1.5	1.3	3.1	2.5	1.7	0.7	0.2	0.0	4.7	7.7	1.3	0.5	10.9	11.2	4.2	7.3	8.7	7.7	11.7	9.4	9.7	7.8	44.7	35.0	7.5	130.2	117.2	0.0	14.4	38.2	10.7	37.5	57.6	0.0	99.2	68.0	79.4	0.8	30.6	3.6	0.0	73.3	72.2	63.2	50.1	8.1	26.8	40.2	1.6	4.7	19.6	7.0	2.2	60.9	26.5	35.4	31.5	10.3	87.6	78.1	10.5	68.2	104.6	3.3	71.1	72.2	0.9	2.5	85.9	111.1	6.1	17.5	140.8
VASP		ENSG00000125753	"Vasodilator stimulated phosphoprotein"	P50552	19	45506579-45526983	"Plasma proteins, Predicted intracellular proteins"		Actin-binding		"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Extravillous trophoblasts: 388.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"eosinophil: 23.6"	"Group enriched"	"Detected in all"	6	"granulocytes: 23.6;monocytes: 10.4"	"Cell line enhanced"	"Detected in all"		"HMC-1: 65.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004612, HPA005724"	Enhanced		Supported	"Plasma membrane,Cell Junctions,Focal adhesion sites"		NA	NA		110000000	"Plasma membrane, Cell Junctions, Focal adhesion sites"		"CAB004612: AB_2213431, HPA005724: AB_1858721"	"unprognostic (3.07e-2)"	"unprognostic (1.07e-2)"	"unprognostic (4.70e-2)"	"unprognostic (7.85e-3)"	"unprognostic (8.31e-2)"	"unprognostic (1.90e-2)"	"prognostic unfavorable (3.49e-5)"	"unprognostic (1.66e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.30e-2)"	"unprognostic (3.64e-3)"	"unprognostic (4.39e-1)"	"prognostic unfavorable (5.91e-7)"	"unprognostic (1.15e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.08e-2)"	29.1	10.3	4.9	33.3	5.9	40.3	19.0	3.9	4.7	22.6	38.2	5.3	15.4	28.8	37.5	13.3	34.3	23.8	32.2	21.1	5.2	4.3	17.9	21.1	30.5	44.5	7.7	2.2	22.5	10.5	2.9	7.5	31.5	6.2	26.8	9.8	8.9	12.9	20.3	10.4	13.0	43.7	36.7	4.8	69.2	33.4	14.4	6.6	28.3	11.7	12.8	33.2	39.2	17.5	1.8	2.6	23.6	10.4	2.0	2.1	2.2	15.5	16.4	4.8	8.2	2.4	4.2	12.3	16.1	12.4	11.1	9.7	7.4	32.8	7.2	13.7	12.8	7.4	14.5	1.4	15.9	3.7	21.2	3.7	41.4	8.1	12.5	13.6	15.1	65.0	6.4	9.0	10.4	6.7	9.0	16.5	6.1	24.7	15.7	6.8	13.0	6.9	13.1	8.4	14.6	11.3	5.2	3.0	2.7	9.5	50.0	5.7	4.0	19.1	9.8	11.3	3.2	10.6	26.0	24.6	17.8	18.0	5.7	25.3	8.4	10.1	12.4	12.4	18.5	21.3	5.6	4.0	23.6	2.1	6.5	1.5	1.8	1.7	2.0	2.6	1.7	1.1	1.3	17.1	2.0	10.4	1.0	1.2	2.2	4.9	5.9	3.9	4.7	5.2	4.3	7.7	2.2	6.2	6.6	14.9	24.5	57.0	75.3	87.2	7.9	14.6	30.6	10.7	34.2	31.4	25.5	54.0	14.9	140.2	2.8	53.3	134.7	0.0	86.8	388.2	29.9	56.5	81.9	13.5	148.4	6.4	110.1	45.4	113.3	3.6	24.2	183.9	47.2	67.7	118.7	13.1	143.6	173.9	46.3	13.6	13.6	129.4	84.5	7.5	10.0	68.0	117.9	82.0	102.2	112.6
VTCN1	"B7-H4, B7H4, B7S1, B7X, FLJ22418"	ENSG00000134258	"V-set domain containing T cell activation inhibitor 1"	Q7Z7D3	1	117143587-117210960	"Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"			"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 46.4;epididymis: 29.9;kidney: 27.0;pancreas: 35.9"	"Group enriched"	"Detected in some"	5	"Collecting duct cells: 52.4;Ductal cells: 73.6;Exocrine glandular cells: 31.1"	"Group enriched"	"Detected in many"	6	"breast cancer: 55.8;endometrial cancer: 45.2;ovarian cancer: 49.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"SK-BR-3: 74.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA054200	Approved		Approved	"Plasma membrane,Cell Junctions,Focal adhesion sites"		No	NA			"Plasma membrane"	"Cell Junctions, Focal adhesion sites"	"HPA054200: AB_2682415"	"unprognostic (4.13e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.95e-1)"	"unprognostic (3.44e-2)"	"unprognostic (1.71e-3)"	"unprognostic (2.56e-1)"	"unprognostic (7.94e-2)"	"unprognostic (4.86e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.17e-2)"	"unprognostic (4.54e-2)"	"unprognostic (5.47e-2)"	"unprognostic (1.50e-2)"	"unprognostic (1.06e-1)"	"unprognostic (2.42e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.45e-2)"	0.1	0.0	0.1	0.1	0.1	0.0	46.4	0.1	0.1	6.7	0.1	0.1	7.0	0.0	2.6	29.9	0.4	14.2	1.9	0.2	0.1	0.1	27.0	0.9	0.3	0.1	0.1	0.1	4.5	35.9	0.0	1.4	3.0	0.1	1.5	0.0	0.1	17.5	3.6	0.2	2.2	0.1	0.8	0.1	0.1	1.5	2.5	0.1	0.2	0.1	0.5	1.5	2.1	0.7	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.5	0.0	0.0	0.0	13.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.3	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.3	0.0	0.0	74.4	0.0	9.6	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	2.4	0.0	0.0	1.2	0.0	4.0	10.3	52.4	0.0	1.7	0.0	73.6	1.6	0.0	0.0	0.0	31.1	1.1	0.0	1.5	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	3.9
ZYX		ENSG00000159840	Zyxin	Q15942	7	143381080-143391111	"Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Host-virus interaction"			"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 188.3;monocytes: 174.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 47.5"	"Group enriched"	"Detected in many"	4	"dendritic cells: 16.5;granulocytes: 47.5;monocytes: 22.1"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004835, CAB009321, HPA073497, CAB075747"	Approved		Supported	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA		420000000	"Focal adhesion sites"	"Plasma membrane, Actin filaments"	"CAB009321: AB_2221290, CAB075747: AB_2665753, HPA004835: AB_1080771, HPA073497: AB_2686611"	"unprognostic (1.96e-2)"	"unprognostic (5.35e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.21e-3)"	"unprognostic (1.66e-3)"	"unprognostic (2.60e-1)"	"unprognostic (4.22e-1)"	"unprognostic (1.98e-1)"	"unprognostic (2.43e-1)"	"prognostic unfavorable (7.92e-5)"	"unprognostic (1.39e-1)"	"unprognostic (8.12e-2)"	"unprognostic (1.95e-1)"	"unprognostic (6.72e-2)"	52.7	11.7	7.7	39.3	8.8	46.1	34.3	17.5	22.2	61.1	56.8	10.7	20.5	13.6	103.6	38.6	52.3	48.9	58.1	22.7	7.4	7.7	24.7	21.2	52.8	63.0	8.8	8.3	58.1	15.9	63.8	9.1	32.4	15.5	43.8	10.8	17.9	18.8	40.7	28.3	21.1	26.6	74.7	8.5	57.1	28.3	37.4	7.1	24.4	18.9	19.1	26.0	93.7	35.7	0.9	16.5	47.5	22.1	4.1	6.7	9.0	12.8	7.8	10.3	14.4	19.5	43.7	12.3	27.3	32.1	30.0	25.2	26.5	8.3	0.8	10.7	33.3	17.3	10.4	6.3	27.6	14.0	13.7	3.4	20.0	9.2	9.2	34.4	16.1	31.9	46.5	12.3	32.7	11.1	18.6	37.9	1.8	4.9	8.7	31.9	14.4	0.2	32.4	21.6	5.0	50.5	3.0	5.5	1.2	22.7	6.8	0.5	7.8	21.5	20.1	11.2	9.8	2.4	16.1	66.4	35.8	14.7	38.0	28.7	2.8	3.7	2.2	31.8	16.9	23.7	4.9	18.2	12.5	5.9	19.2	4.7	0.9	5.5	6.7	16.5	0.5	3.5	4.0	47.5	4.1	22.1	4.2	5.0	9.0	7.7	8.8	17.5	22.2	7.4	7.7	8.8	8.3	15.5	7.1	6.0	8.3	17.4	144.9	30.0	3.3	10.9	33.1	2.7	27.3	33.2	0.0	28.4	6.6	98.9	1.5	40.4	21.3	0.0	81.4	80.5	41.1	47.9	35.8	26.7	153.1	0.0	36.7	66.9	188.3	4.7	26.4	86.6	13.5	174.9	19.9	15.1	120.5	31.6	51.9	14.7	2.6	84.1	82.1	7.9	9.5	17.7	23.5	54.9	19.6	87.0
